

Juan Valle  
Honorary  
Division of Cancer Sciences (L5)



## Employment

### Emeritus Professor

Honorary

Division of Cancer Sciences (L5)

The University of Manchester

12 Jan 2024 → present

## Research outputs

### **Updated overall survival and outcomes of long-term survivors from the randomised phase 3 TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer**

Mcnamara, M. G., Valle, J. W. & al, E., 22 Mar 2024, (Accepted/In press) In: The Lancet Gastroenterology and Hepatology.

### **Advanced intrahepatic cholangiocarcinoma with extrahepatic metastasis and high tumour mutation burden: A case report of complete pathological response to cisplatin/gemcitabine and pembrolizumab**

Robinson, M., Wheatley, R., Foster, L., Jamdar, S., Siriwardena, A. K., Lamarca, A., Hubner, R., Valle, J. & Mcnamara, M., 21 Feb 2024, (Accepted/In press) In: JCO Precision Oncology.

### **British Society of Gastroenterology Guidelines for the Diagnosis and Management of Cholangiocarcinoma**

Rushbrook, S., Kendall, T. J., Zen, Y., Albazaz, R., Manoharan, P., Pereira, S. P., Sturgess, R., Davidson, B., Malik, H., Manas, D., Heaton, N., Prasad, R., Bridgewater, J., Valle, J. W., Goody, R., Hawkins, M., Prentice, W., Morement, H., Walmsley, M. & Khan, S. A., 1 Jan 2024, In: Gut. 73, 1

### **The clinical utility of plasma cell-free DNA (cfDNA) in NET-02: Randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).**

Mcnamara, M., Pearce, S., Swain, J., Halford, M. A., Sharma, R., Faluyi, O. O., Wadsley, J., Morgan, C., Wall, L. R., Chau, I., Reed, N., Sarker, D., Margetts, J., Anthoney, A., Oughton, J. B., Lamarca, A., Hubner, R., Rothwell, D. G., Valle, J. W. & Clipson, A., 2024.

### **Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): what is the recent evidence?**

Passhak, M., Mcnamara, M. G., Hubner, R. A., Ben-Aharon, I. & Valle, J. W., 2 Nov 2023, In: Best Practice and Research: Clinical Endocrinology and Metabolism. 37, 5, 101836.

### **Prognosis discussion and referral to community palliative care services in patients with advanced pancreatic cancer treated in a tertiary cancer centre**

Clelland, S., Nuttall, C. L., Stott, H. E., Cope, J., Barratt, N. L., Farrell, K., Eyong, M., Gleeson, J. P., Lamarca, A., Hubner, R. A., Valle, J. W. & Mcnamara, M. G., 23 Oct 2023, In: Healthcare. 11, 20, 2802.

### **Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma**

Weaver, J. M. J., Hubner, R., Valle, J. & Mcnamara, M., 11 Oct 2023, In: Cancers. 15, 20, 4951.

### **Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy**

d'Abrigeon, C., McNamara, M. G., Le Sourd, S., Lamarca, A., Lièvre, A., Bourien, H., Peinoit, A., Uguen, T., Hubner, R. A., Valle, J. W. & Edeline, J., 9 Oct 2023, In: British Journal of Cancer.

**Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer**  
Mcnamara, M., Valle, J. W. & et al., 25 Sept 2023, In: Future oncology (London, England).

**Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma**

Foy, V., Mcnamara, M., Valle, J., Lamarca, A., Edeline, J. & Hubner, R., 21 Sept 2023, In: Current Oncology. 30, 9, p. 8665-8685 21 p.

**Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma**

Lamarca, A., Ostios, L., Mcnamara, M. G., Garzon, C., Gleeson, J. P., Edeline, J., Herrero, A., Hubner, R. A., Moreno, V. & Valle, J. W., 16 Sept 2023, (E-pub ahead of print) In: Cancer Treatment Reviews. 102627.

**Patients Undergoing Systemic Anti-Cancer Therapy Who Require Surgical Intervention: What Surgeons Need to Know**

Robinson, M., Mcnamara, M. G., Clouston, H. W., Sutton, P. A., Hubner, R. A. & Valle, J. W., 26 Jul 2023, (E-pub ahead of print) In: Cancers. 15, 15, 3781.

**EASL-ILCA Clinical Practice Guidelines on Intrahepatic Cholangiocarcinoma.**

Alvaro, D., Gores, G. J., Walicki, J., Hassan, C., Sapisochin, G., Komuta, M., Forner, A., Valle, J. W., Laghi, A., Rizvi, S. I., Park, J.-W., Kelley, R. K., Reig, M. & Sangro, B., 1 Jul 2023, In: Journal of hepatology. 1, 28, p. 181-208

**Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes**

Gray, S., Letissier, O., D'abrigion, C., Shah, D., Wardell, S., Faluyi, O., Lamarca, A., Hubner, R. A., Edeline, J., Valle, J. W. & Mcnamara, M. G., 3 Jun 2023, In: Cancers. 15, 11, 3047.

**NET-02: A randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma**

Mcnamara, M., Lamarca, A., Hubner, R., Valle, J. & al, E., 2 Jun 2023, In: EClinicalMedicine. 60, 102015.

**The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study**

Hall, L. A., McKay, S. C., Halle-Smith, J., Soane, J., Osei-Bordom, D.-C., Goodburn, L., Magill, L., Pinkney, T., Radhakrishna, G., Valle, J. & Corrie, P., 11 May 2023, In: British Journal of Cancer. p. 1922-1932 128.

**Targeting PD-1/PD-L1 in biliary tract cancer; role and available data**

Mahmood, R. D., Graham, K., Gleeson, J., Hubner, R. A., Valle, J. W. & Mcnamara, M. G., 1 May 2023, In: Immunotherapy. 15, 7, p. 517-530 14 p.

**Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial**

The KEYNOTE-966 Investigators, Kelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., Yau, T., Klumpen, H.-J., Chan, S. L., Ozaka, M., Verslype, C., Bouattour, M., Park, J. O., Barajas, O., Pelzer, U., Valle, J. W., Yu, L., Malhotra, U. & Siegel, A. B. & 2 others, Edeline, J. & Vogel, A., 16 Apr 2023, (E-pub ahead of print) In: The Lancet.

**Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy (PANcreatic Cancer Dietary Assessment—PanDA)**

Carnie, L. E., Shah, D., Vaughan, K., Kapacee, Z. A., McCallum, L., Abraham, M., Backen, A., Mcnamara, M. G., Hubner, R. A., Barriuso, J., Gillespie, L., Lamarca, A. & Valle, J. W., 13 Apr 2023, In: Cancers. 15, 8, 2277.

**Future therapeutic strategies in the treatment of extra-pulmonary neuroendocrine carcinoma: A systematic review**

Robinson, M. D., Livesey, D., Hubner, R. A., Valle, J. W. & Mcnamara, M. G., 1 Mar 2023, (E-pub ahead of print) In: Therapeutic Advances in Medical Oncology. 15

**Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis and prognostication of cholangiocarcinoma**

Lapitz, A., Azkargorta, M., Milkiewicz, P., Olaizola, P., Zhuravieva, E., Grimsrud, M. M., Schramm, C., Arbelaiz, A., O'rouke, C. J., La casta, A., Milkiewicz, M., Pastor, T., Vesterhus, M., Jimenez-Agüero, R., Dill, M. T., Lamarca, A., Valle,

J. W., Macias, R. I. R., Izquierdo-Sanchez, L. & Castaño, Y. P. & 15 others, Caballero-Camino, F. J., Riaño, I., Krawczyk, M., Ibarra, C., Bustamante, J., Nova-Camacho, L. M., Falcon-Perez, J. M., Elortza, F., Perugorria, M. J., Andersen, J. B., Bujanda, L., Karlsen, T. H., Folseraas, T., Rodrigues, P. M. & Banales, J. M., 1 Mar 2023, (E-pub ahead of print) In: *Journal of hepatology*.

**Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma**

Dayimu, A., Di Iisio, L., Anand, S., Roca-Carreras, I., Qian, W., Al-Mohammad, A., Basu, B., Valle, J. W., Jodrell, D., Demiris, N. & Corrie, P., 22 Feb 2023, (E-pub ahead of print) In: *British Journal of Cancer*.

**Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer**

Pihlak, R., Frizziero, M., Mak, S. Y. G., Nuttall, C., Lamarca, A., Hubner, R. A., Valle, J. W. & Mcnamara, M. G., 25 Jan 2023, In: *Cancers*. 15, 3, p. 738

**Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma**

The FOENIX-CCA2 Study Investigators, Goyal, L., Meric-Bernstam, F., Villejuif, G., Valle, J. W., Morizane, C., Karasic, T. B., Abrams, T. A., Furuse, J., Kelley, R. K., Cassier, P. A., Klumpen, H.-J., Chang, H.-M., Chen, L.-T., Taberero, J., Oh, D.-Y., Mahipal, A., Moehler, M., Mitchell, E. P. & Komatsu, Y. & 11 others, Masuda, K., Ahn, D., Epstein, R. S., Halim, A.-B., Fu, Y., Salimi, T., Wacheck, V., He, Y., Liu, M., Benhadji, K. A. & Bridgewater, J. A., 19 Jan 2023, In: *New England Journal Of Medicine*. 388, 3, p. 228-239 12 p.

**ABC-12: Exploring the microbiome in patients (pts) with advanced biliary tract cancer (BTC) in a first-line study of durvalumab in combination with cisplatin/gemcitabine (cis/gem)**

Mcnamara, M., Timmons, H., Osborne, A., Cox, R., Wasan, H., Corrie, P., Gillmore, R., Sivakumar, S., Ma, Y. T., Faluyi, O., Arora, A., Arif, S., Canham, J., Hurt, C., Hubner, R. A., Bridgewater, J., Adams, R. & Valle, J. W., 2023.

**Advanced extrahepatic cholangiocarcinoma: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials**

Lamarca, A., Ross, P. J., Wasan, H. S., Hubner, R., Mcnamara, M., Lopes, A., Palmer, D., Valle, J. & Bridgewater, J. A., 2023.

**Basket trials in upper gastrointestinal and hepato-pancreatico-biliary cancers: an emerging entity**

Huddar, P., Graham, K., Hubner, R., Valle, J. & Mcnamara, M., 2023.

**Frequency of dihydropyrimidine dehydrogenase (DPD) deficiency detection and adverse events in patients receiving fluoropyrimidine-based therapy in a pancreatic and biliary tract cancer cohort**

Wilson, E., Monaghan, P., Gleeson, J., Lamarca, A., Hubner, R., Valle, J. & Mcnamara, M., 2023.

**NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC).**

Mcnamara, M., Swain, J., Craig, Z., Sharma, R., Faluyi, O., Wadsley, J., Morgan, C., Wall, L. R., Chau, I., Reed, N., Sarker, D., Margetts, J., Krell, D., Cave, J., Sothi, S., Anthoney, A., Patel, A., Lamarca, A., Hubner, R. A. & Valle, J. W., 2023.

**Biliary tract cancer: ESMO Clinical Practice Guideline for Peer Review diagnosis, treatment and follow-up**

ESMO Guidelines Committee, 25 Oct 2022, (Accepted/In press) In: *Annals of Oncology*.

**The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC)**

Wheatley, R. C., Valle, J. W. & Mcnamara, M. G., Oct 2022, In: *Hepatobiliary Surgery and Nutrition*. p. 0-0

**What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)?: a retrospective review of the published literature**

Mcnamara, M. G., Bridgewater, J., Goyal, L., Jacobs, T., Wagner, A. D., Goldstein, D., Shroff, R. T., Moehler, M., Lowery, M., Bekaii-Saab, T., Kelley, R. K., Furuse, J., Rimassa, L., Morizane, C., Lamarca, A., Hubner, R., Knox, J. J. & Valle, J. W., 22 Sept 2022, (Accepted/In press) In: *BMJ Open*.

**Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma**

Gray, S., Lamarca, A., Mcnamara, M. G., Edeline, J., Piper Hanley, K., Valle, J. & Hubner, R., 30 Aug 2022, (Accepted/In press) In: Liver Cancer International.

**ALBI grade predicts suitability for further systemic therapy following sorafenib in patients with advanced hepatocellular carcinoma.**

Fakih, O., Haddad, S. S., Walker, S., Edeline, J., Estrade, F., Wang, X., Lamarca, A., Mcnamara, M. G., Valle, J. W. & Hubner, R. A., 5 Aug 2022, (Accepted/In press) In: Liver Cancer International.

**Management and outcomes of patients with extra-pulmonary neuroendocrine neoplasms and brain metastases**

Kapacee, Z. A., Allison, J., Dawod, M., Frizziero, M., Chakrabarty, B., Manoharan, P., McBain, C., Mansoor, W., Lamarca, A., Hubner, R., Valle, J. & Mcnamara, M. G., 13 Jul 2022, (Accepted/In press) In: Current Oncology.

**Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10mm in diameter**

Exarchou, K., Hu, H., Stephens, N. A., Moore, R. A., Kelly, M., Lamarca, A., Mansoor, W., Hubner, R., Mcnamara, M. G., Smart, H., Howes, N. R., Valle, J. W. & Pritchard, D. M., 9 Jul 2022, (Accepted/In press) In: Endocrine.

**Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignancies**

Shah, D., Kapacee, Z. A., Lamarca, A., Hubner, R. A., Valle, J. W. & Mcnamara, M. G., 6 Jul 2022, In: Expert Review of Anticancer Therapy. 22, 9, p. 1009-1015 7 p.

**Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study**

Bridgewater, J., Fletcher, P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D., Anthony, A., Corrie, P., Falk, S., Finch-Jones, M., Wasan, H., Ross, P., Wall, L., Wadsley, J., Evans, T. R., Stocken, D., Stubbs, C., Praseedom, R., Ma, Y. T. & Davidson, B. & 6 others, Neoptolemos, J., Iveson, T., Cunningham, D., Garden, O. J., Valle, J. W. & Primrose, J., 20 Jun 2022, In: Journal of Clinical Oncology. 40, 18, p. 2048-2057 10 p.

**Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers**

Zhou, C., O'Connor, J., Backen, A., Valle, J., Bridgewater, J. A., Dive, C. & Jayson, G. (Corresponding), 1 Apr 2022, In: ESMO Open. 7, 2, 100417.

**Targeted Therapies for Perihilar Cholangiocarcinoma**

Gray, S., Lamarca, A., Edeline, J., Klumpfen, H.-J., Hubner, R. A., Mcnamara, M. G. & Valle, J. W., 1 Apr 2022, In: Cancers. 14, 7, p. 1789 1789.

**Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary**

Conway, A.-M., Morris, G. C., Smith, S., Vekeria, M., Manoharan, P., Mitchell, C., Backen, A., Oliveira, P., Hubner, R., Lamarca, A., Mcnamara, M., Valle, J. & Cook, N., 29 Mar 2022, (Accepted/In press) In: British Journal of Cancer..

**Markers of tumour inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first line FOLFIRINOX chemotherapy**

Kamosioras, K., Papaxoinis, G., Dawood, M., Appleyard, J., Collinson, F., Lamarca, A., Ahmad, U., Hubner, R. A., Wright, F., Pihlak, R., Damyanova, I., Razzaq, B., Valle, J., Mcnamara, M. & Anthoney, A., 11 Mar 2022, (Accepted/In press) In: Acta Oncologica .

**Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The role of ctDNA in Real World Practice**

Lamarca, A., Frizziero, M., Barriuso, J., Kapacee, Z. A., Mansoor, W., Mcnamara, M., Hubner, R. A. & Valle, J., 17 Feb 2022, In: Cancers.

**Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry**

Izquierdo-sanchez, L., Lamarca, A., La Casta, A., Buettner, S., Utpatel, K., Klumpfen, H.-J., Adeva, J., Vogel, A., Lleo, A., Fabris, L., Ponz-sarvisse, M., Brustia, R., Cardinale, V., Braconi, C., Vidili, G., Jamieson, N. B., Macias, R. I., Jonas, J. P., Marzioni, M. & Hołowko, W. & 24 others, Folseraas, T., Kupčinskis, J., Sparchez, Z., Krawczyk, M., Krupa, Ł., Scripcariu, V., Grazi, G. L., Landa-magdalena, A., Ijzermans, J. N., Evert, K., Erdmann, J. I., López-lópez, F., Saborowski, A., Scheiter, A., Santos-laso, A., Carpino, G., Andersen, J. B., Marin, J. J., Alvaro, D., Bujanda, L., Forner, A., Valle, J. W.,

Koerkamp, B. G. & Banales, J. M., 12 Feb 2022, In: Journal of hepatology.

**Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma**

Gray, S., de Liguori-Carino, N., Radhakrishna, G., Lamarca, A., Hubner, R. A., Valle, J. W. & Mcnamara, M. G., 10 Feb 2022, (Accepted/In press) In: European Journal of Surgical Oncology.

**Expanding therapeutic opportunities for Extra-Pulmonary Neuroendocrine Carcinoma**

Frizziero, M., Kilgour, E., Simpson, K. L., Rothwell, D. G., Moore, D. A., Frese, K. K., Galvin, M., Lamarca, A., Hubner, R. A., Valle, J. W., Mcnamara, M. G. & Dive, C., 28 Jan 2022, In: Clinical Cancer Research.

**Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy**

D'abrigeon, C., Mcnamara, M., LeSourd, S., Lamarca, A., Lievre, A., Hubner, R., Valle, J. & Edeline, J., 2022.

**NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).**

Mcnamara, M., Swain, J., Craig, Z., Sharma, R., Faluyi, O., Wadsley, J., Morgan, C., Wall, L. R., Chau, I., Reed, N., Sarker, D., Margetts, J., Krell, D., Cave, J., Sharmila, S., Anthony, A., Patel, A., Lamarca, A., Hubner, R. A. & Valle, J., 2022.

**Prognosis discussion and referral to community palliative care services (CPCS) in patients with advanced pancreas cancer (APC)**

Clelland, S., Nuttall, C., Stott, H., Cope, J., Barratt, N., Farrell, K., Eyong, M., Lamarca, A., Hubner, R., Valle, J. & Mcnamara, M., 2022, p. 120–124. 5 p.

**Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis**

Lee, B. Y., Hogg, E., Below, C., Kononov, A., Blanco Gomez, A., Heider, F., Xu, J., Hutton, C., Zhang, X., Scheidt, T., Beattie, K., Lamarca, A., Mcnamara, M., Valle, J. & Jorgensen, C., 17 Dec 2021, In: Nature Communications. 12, 1, 7336.

**Set up of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)**

Casadio, M., Cardinale, V., Klumpfen, H.-J., Morement, H., Lacasta, A., Koerkamp, B. G., Banales, J. M., Alvaro, D., Valle, J. & Lamarca, A., 15 Dec 2021, (Accepted/In press) In: ESMO Open.

**Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy**

Wheatley, R., Kilgour, E., Jacobs, T., Lamarca, A., Hubner, R. A., Valle, J. & Mcnamara, M., 4 Oct 2021, (Accepted/In press) In: BJC.

**Pancreatic Enzyme Replacement Therapy for Patients Diagnosed With Pancreaticobiliary Cancer: Validation of an Algorithm for Dose Escalation and Management**

Carnie, L. E., Farrell, K., Barratt, N., Abraham, M., Gillespie, L., Satyadas, T., Mcnamara, M. G., Hubner, R. A., Geraghty, J., Bibby, N., Valle, J. W. & Lamarca, A., 1 Oct 2021, In: Pancreas. 50, 9, p. 1254-1259

**Everolimus-induced pneumonitis in patients with neuroendocrine neoplasms: real-world study on risk factors and outcomes**

Taboada, R. G., Riechelmann, R. P., Mauro, C., Barros, M., Hubner, R., Mcnamara, M., Lamarca, A. & Valle, J., 29 Sept 2021, (Accepted/In press) In: The oncologist.

**Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis**

Broadbent, R., Wheatley, R., Stajer, S., Jacobs, T., Lamarca, A., Hubner, R., Valle, J., Amir, E. & Mcnamara, M., 5 Sept 2021, (Accepted/In press) In: Cancer Treatment Reviews.

**Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis**

Edeline, J., Lamarca, A., Mcnamara, M. G., Jacobs, T., Hubner, R. A., Palmer, D., Groot Koerkamp, B., Johnson, P., Guiu, B. & Valle, J. W., 1 Sept 2021, In: Cancer Treatment Reviews. 99, 102258.

**Is the morphological subtype of Extra-Pulmonary Neuroendocrine Carcinoma clinically relevant?**

Frizziero, M., Durand, A., Taboada, R. G., Zaninotto, E., Luchini, C., Chakrabarty, B., Hervieu, V., Claro, L. C. L., Zhou, C., Cingarlini, S., Milella, M., Walter, T., Riechelmann, R. S., Lamarca, A., Hubner, R., Mansoor, W., Valle, J. & Mcnamara, M., 13 Aug 2021, (Accepted/In press) In: Cancers.

**Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review**

Shotton, R., Lamarca, A., Valle, J. & Mcnamara, M., 11 Aug 2021, In: World Journal of Gastrointestinal Oncology.

**The Microbiome As A Potential Target For Therapeutic Manipulation In Pancreatic Cancer**

Rahman, R., Lamarca, A., Hubner, R. A., Valle, J. & Mcnamara, M., 1 Aug 2021, In: Cancers. 13, 15, 3779.

**Randomized phase 2 study of the addition of ramucirumab or merestinib to standard first line therapy for advanced or metastatic biliary tract cancer**

Valle, J. & et al., 6 Jul 2021, (Accepted/In press) In: Lancet Oncology.

**Final Overall Survival Results From a Phase 3 Study of Ivosidenib in IDH1-Mutant, Advanced Cholangiocarcinoma (ClarIDHy): A Randomized Clinical Trial**

Valle, J., Jul 2021, In: JAMA oncology.

**Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity**

Hutton, C., Heider, F., Blanco Gomez, A., Banyard, A., Kononov, A., Zhang, X., Karim, S. A., Paulus-Hock, V., Watt, D., Steele, N., Kemp, S., Hogg, E., Kelly, J., Jackstadt, R.-F., Lopes, F., Menotti, M., Chisholm, L., Lamarca, A., Valle, J. & Sansom, O. J. & 7 others, Springer, C., Malliri, A., Marais, R., di Magliano, M. P., Zelenay, S., Morton, J. P. & Jorgensen, C., 25 Jun 2021, (Accepted/In press) In: Cancer Cell.

**Next-Generation Biomarkers for Cholangiocarcinoma**

Rodrigues, P. M., Vogel, A., Arrese, M., Balderramo, D. C., Valle, J. & Banales, J. M., 22 Jun 2021, (Accepted/In press) In: Cancers.

**Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group**

Kössler, T., Alsina, M., Arnold, D., Ben-Aharon, I., Lutz, M. B., Obermannova, R., Peeters, M., Sclafani, F., Smyth, E., Valle, J., Wagner, A. D., Wyrwicz, L., Fontana, E. & Moehler, M., 17 Jun 2021, (Accepted/In press) In: British Journal of Cancer.

**Resected Pancreatic Ductal Adenocarcinoma: understanding tumour tropism to maximise benefit from surgery.**

Frizziero, M., Purohit, A., Malik, A. K., Deshpande, R., Mcnamara, M., Satyadas, T., Jamdar, S., Pihlak, R., Sheen, A., Siriwardena, A., Hubner, R., O'Reilly, D., Valle, J., de Liguori-Carino, N. & Lamarca, A., Jun 2021, In: Journal of Cancer Research and Clinical Oncology.

**The impact of 68Gallium DOTA PET/CT in managing patients with sporadic and familial pancreatic neuroendocrine tumours**

Cuthbertson, D. J., Barriuso, J., Lamarca, A., Manoharan, P., Westwood, T., Jaffa, M., Fenwick, S. W., Nuttall, C., Lalloo, F., Prachalias, A., Pizanas, M., Wiesmann, H., Mcnamara, M., Hubner, R., Srirajaskanthan, R., Vivian, G., Ramage, J., Weickert, M. O., Pritchard, D. M. & Vinjamuri, S. & 2 others, Valle, J. & Yip, V., 11 May 2021, (Accepted/In press) In: Frontiers in Endocrinology.

**Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)**

Capdevila, J., Fazio, N., Lopez, C., Teulé, A., Valle, J. W., Tafuto, S., Custodio, A., Reed, N., Raderer, M., Grande, E., Garcia-carbonero, R., Jimenez-fonseca, P., Hernando, J., Bongiovanni, A., Spada, F., Alonso, V., Antonuzzo, L., Spallanzani, A., Berruti, A. & La Casta, A. & 9 others, Sevilla, I., Kump, P., Giuffrida, D., Merino, X., Trejo, L., Gajate, P., Matos, I., Lamarca, A. & Ibrahim, T., 4 May 2021, (E-pub ahead of print) In: Journal of Clinical Oncology.

**Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial**

Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., Falk, S., Gillmore, R., Wadsley, J., Patel, K., Anthony, A., Maraveyas, A., Iveson, T., Waters, J. S., Hobbs, C., Barber, S., Ryder, W. D., Ramage, J., Davies, L. M. & Bridgewater, J. A. & 1 others, Valle, J. W., 1 May 2021, In: *The Lancet Oncology*. 22, 5, p. 690-701

**Long-term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study**

Hörsch, D., Anthony, L. B., Gross, D. J., Valle, J., Welin, S., Benavent, M., Caplin, M. E., Pavel, M., Bergsland, E., Öberg, K., Kassler-Taub, K. B., Binder, P., Banks, P., Lapuerta, P. & Kulke, M. H., 27 Apr 2021, (Accepted/In press) In: *Neuroendocrinology*.

**Response to letter regarding 'Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?'**

Kapacee, Z. A., Mcnamara, M., de Liguori-Carino, N., Lamarca, A., Valle, J. & Hubner, R., 12 Apr 2021, (Accepted/In press) In: *European Journal of Surgical Oncology*.

**Baseline Interleukin-6 and 8 Predict Response and Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib Monotherapy: An Exploratory Post-hoc Analysis of the SORAMIC Trial**

Valle, J. & et al., 29 Mar 2021, (Accepted/In press) In: *Journal of Cancer Research and Clinical Oncology*.

**Chemotherapy for Advanced Gallbladder Cancer (GBC): A Systematic Review and Meta-Analysis**

Azizi, A. A., Lamarca, A., Mcnamara, M. & Valle, J., 26 Mar 2021, (Accepted/In press) In: *Critical Reviews in Oncology/Hematology*.

**Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment - PanDA): a study protocol**

Carnie, L., Lamarca, A., Vaughan, K., Kapacee, Z. A., McCallum, L., Backen, A., Barriuso, J., Mcnamara, M., Hubner, R., Abraham, M. & Valle, J., 12 Mar 2021, (Accepted/In press) In: *BMJ Open*.

**Ivosidenib: an investigational drug for the treatment of biliary tract cancer**

Angelakas, A., Lamarca, A., Hubner, R., Mcnamara, M. & Valle, J., 3 Mar 2021, (Accepted/In press) In: *Expert Opinion on Investigational Drugs*.

**Relationship Between Metabolic Toxicity and Efficacy of Everolimus in Patients With Neuroendocrine Tumors: A Pooled Analysis From the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials**

Fazio, N., Carnaghi, C., Buzzoni, R., Valle, J., Herbst, F., Ridolfi, A., Strosberg, J., Kulke, M. H., Pavel, M. & Yao, J. C., 2 Mar 2021, (Accepted/In press) In: *Cancer*.

**Reply to "Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?"; multiple primaries vs liver metastases**

Lamarca, A., Santos-Iaso, A., Utpatel, K., La Casta, A., Stock, S., Forner, A., Adeva, J., Folseraas, T., Fabris, L., Macias, R. I., Krawczyk, M., Krawczyk, M., Cardinale, V., Braconi, C., Alvaro, D., Evert, M., Banales, J. M. & Valle, J. W., 7 Feb 2021, (E-pub ahead of print) In: *Hepatology*.

**Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: a systematic review and meta-analysis**

Garcia-Torralba, E., Spada, F., Lim, K. H. J., Jacobs, T., Barriuso, J., Mansoor, W., Mcnamara, M., Hubner, R., Manoharan, P., Fazio, N., Valle, J. & Lamarca, A., 5 Feb 2021, (Accepted/In press) In: *Cancer Treatment Reviews*.

**External validity of somatostatin analogues trials in advanced neuroendocrine neoplasms: the GETNE-TRASGU study**

Jimenez-fonseca, P., Carmona-bayonas, A., Lamarca, A., Barriuso, J., Castaño, A., Benavent, M., Alonso, V., Riesco, M. D. C., Alonso-gordoa, T., Custodio, A., Sanchez Canovas, M., Hernando, J., López, C., La Casta, A., Fernandez Montes, A., Marazuela, M., Crespo, G., Diaz, J. A., Feliciangeli, E. & Gallego, J. & 8 others, Llanos, M., Segura, A., Vilardell, F., Percovich, J. C., Grande, E., Capdevila, J., Valle, J. & Garcia-carbonero, R., 28 Jan 2021, In: *Neuroendocrinology*. 0, 0.

**The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms**  
Shah, D., Lamarca, A., Valle, J. & Mcnamara, M., 16 Jan 2021, (Accepted/In press) In: Journal of Clinical Medicine.

**NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer**  
Mcnamara, M. & Valle, J., 15 Jan 2021, (Accepted/In press) In: The oncologist.

**Randomised Phase III Controlled Trial of FOLFOX as Second-line Chemotherapy for Advanced Biliary Tract Cancer**  
Lamarca, A., Palmer, D. H., Barber, S., Ryder, D., Davies, L. & Valle, J., 12 Jan 2021, (Accepted/In press) In: Lancet Oncology.

**Assessing the management of bone metastases in patients diagnosed with neuroendocrine neoplasms: Re-audit of clinical practice**  
Garcia-Torralba, E., Lim, K., Barriuso, J., Mcnamara, M., Hubner, R., Mansoor, W., Valle, J. & Lamarca, A., 2021.

**Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials**  
Bourien, H., Lamarca, A., Mcnamara, M., Hubner, R. A., Valle, J. & Edeline, J., 2021, In: Expert Opinion on Investigational Drugs.

**Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).**  
Mcnamara, M., Bridgewater, J., Goyal, L., Goldstein, D., Shroff, R. T., Moehler, M. H., Lowery, M. A., Bekaii-Saab, T. S., Kelley, R. K., Furuse, J., Rimassa, L., Morizane, C., Lamarca, A., Hubner, R., Knox, J. J. & Valle, J., 2021.

**Generation of a Circulating Tumour Cell (CTC)-Derived eXplant of a NeuroEndocrine Carcinoma of unknown origin**  
Frizziero, M., Kilgour, E., Simpson, K., Frese, K., Valle, J., Mcnamara, M. & Dive, C., 2021.

**Incidence of brain metastases (BMs) and outcomes in patients (pts) with extrapulmonary neuroendocrine neoplasms (EP-NENs).**  
Kapacee, Z., Dawod, M., Allison, J., Frizziero, M., Chakrabarty, B., Manoharan, P., McBain, C., Mansoor, W., Lamarca, A., Hubner, R., Valle, J. & Mcnamara, M., 2021.

**Intrahepatic cholangiocarcinoma (iCCA) hidden amongst the unknown: A retrospective analysis of cancer of unknown primary (CUP) cases from a tertiary cancer centre**  
Conway, A., Morris, G., Smith, S., Manoharan, P., Mitchell, C., Backen, A., Oliveira, P., Hubner, R., Lamarca, A., Mcnamara, M., Valle, J. & Cook, N., 2021.

**Liquid biopsy-based precision-medicine for Extra-Pulmonary Neuroendocrine Carcinomas**  
Frizziero, M., Kilgour, E., Simpson, K., Frese, K., Valle, J., Mcnamara, M. & Dive, C., 2021.

**Molecular profiling of advanced pancreatic ductal adenocarcinoma (PDAC): Role of ctDNA.**  
Lamarca, A., Mcnamara, M., Hubner, R. & Valle, J., 2021.

**Molecular profiling of well-differentiated neuroendocrine tumors: Role of ctDNA**  
Lamarca, A., Frizziero, M., Barriuso, J., Kapacee, Z., Mansoor, W., Mcnamara, M., Hubner, R. & Valle, J., 2021.

**Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): A systematic review and meta-analysis**  
Broadbent, R., Wheatley, R., Stajer, S., Jacobs, T., Lamarca, A., Hubner, R. A., Valle, J., Amir, E. & Mcnamara, M., 2021.

**Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency (PEI) in patients with advanced pancreatic cancer (aPC): PanDA**  
Lamarca, A., Carnie, L., Shah, D., Vaughan, K., Abedin Kapacee, Z., McCallum, L., Abraham, M., Backen, A., Mcnamara, M., Hubner, R., Barriuso, J., Gillespie, L. & Valle, J., 2021.



**Role of ctDNA to predict risk of recurrence following potentially curative resection of biliary tract and pancreatic malignancies.**

Lamarca, A., Mcnamara, M., Hubner, R. & Valle, J., 2021.

**Incidence and outcomes of brain metastases in patients with extra-pulmonary neuroendocrine neoplasms**

Kapacee, Z., Dawod, M., Allison, J., Frizziero, M., Chakrabarty, B., Manoharan, P., McBain, C., Mansoor, W., Lamarca, A., Hubner, R., Valle, J. & Mcnamara, M., 9 Nov 2020, p. ii123-ii124.

**HPB cancers in older patients: Inclusion of elderly patients in clinical trials**

Backen, A., Lamarca, A., Hubner, R., Mcnamara, M. & Valle, J., 2 Nov 2020, (Accepted/In press) In: European Journal of Surgical Oncology.

**A phase Ib study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08)**

Mcnamara, M., Bridgewater, J., Palmer, D. H., Faluyi, O., Wasan, H., Patel, A., Ryder, W. D., Barber, S., Gnanaranjan, C., Ghazaly, E., Evans, T. R. J. & Valle, J., 30 Oct 2020, (Accepted/In press) In: Oncologist.

**Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System**

Lamarca, A., Santos-Laso, A., Utpatel, K., La Casta, A., Stock, S., Forner, A., Adeva, J., Folseraas, T., Fabris, L., Macias, R. I. R., Krawczyk, M., Krawczyk, M., Cardinale, V., Braconi, C., Alvaro, D., Evert, M., Banales, J. M. & Valle, J., 21 Sept 2020, (Accepted/In press) In: Hepatology.

**Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer**

Carnie, L., Abraham, M., Mcnamara, M. G., Hubner, R. A., Valle, J. W. & Lamarca, A., 14 Sept 2020, (E-pub ahead of print) In: Pancreatology.

**Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers**

Lamarca, A., Kapacee, Z., Breeze, M., Bell, C., Belcher, D., Staiger, H., Taylor, C., Mcnamara, M. G., Hubner, R. A. & Valle, J. W., 3 Sept 2020, (E-pub ahead of print) In: Journal of Clinical Medicine. 9, 9, p. 2854

**Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters using the Modified RAND/UCLA Delphi Process**

Valle, J. & et al., 17 Aug 2020, (Accepted/In press) In: Cancers.

**Impact of high tumor mutational burden in solid tumors and challenges for biomarker application**

Mcnamara, M., Jacobs, T., Lamarca, A., Hubner, R., Valle, J. & Amir, E., 16 Jul 2020, (Accepted/In press) In: Cancer Treatment Reviews.

**Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)**

Megdanova-Chipeva, V. G., Lamarca, A., Backen, A., Mcnamara, M., Barriuso, J., Sergieva, S., Gocheva, L., Mansoor, W., Manoharan, P. & Valle, J., 9 Jul 2020, (Accepted/In press) In: Cancers.

**Fibrolamellar Carcinoma: challenging the challenge**

Lamarca, A., Frizziero, M., Fulton, A., Mcnamara, M., Filobbos, R., Wardell, S. & Valle, J., 1 Jul 2020, (Accepted/In press) In: European Journal of Cancer.

**Molecular targeted therapies: ready for "prime time" in biliary tract cancer**

Lamarca, A., Barriuso, J., Mcnamara, M. & Valle, J., Jul 2020, In: Journal of Hepatology. 73, 1, p. 170-185 16 p.

**FIGHT-302: First-line pemigatinib vs gemcitabine + cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements**

Valle, J. & et al., 17 Jun 2020, (Accepted/In press) In: Future Oncology.

**NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials**

Kapacee, Z. A., Knox, J. J., Palmer, D., Blagden, S. P., Lamarca, A., Valle, J. & Mcnamara, M., 1 Jun 2020, (Accepted/In press) In: Medical Oncology.

**Randomised phase 3 study of ivosidenib in IDH1-mutant chemotherapy-refractory cholangiocarcinoma**

Valle, J. & et al., 1 Jun 2020, (Accepted/In press) In: Lancet Oncology.

**Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis**

Buettner, S., Braat, A. J. A. T., Margonis, G. A., Brown, D. B., Taylor, K. B., Borgmann, A. J., Kappadath, S. C., Mahvash, A., Ijzermans, J. N. M., Weiss, M. J., Lamarca, A., Bell, J. K., Valle, J. W., Hagendoorn, J., Koerkamp, B. G., Sze, D. Y. & Lam, M. G. E. H., 28 May 2020, (E-pub ahead of print) In: Journal of Vascular and Interventional Radiology.

**Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer**

Mcnamara, M., Lopes, A., Wasan, H., Malka, D., Goldstein, D., Shannon, J., Okusaka, T., Knox, J. J., Wagner, A. D., Andre, T., Cunningham, D., Moehler, M., Jensen, L. H., Koeberle, D., Bekaii-Saab, T., Bridgewater, J. & Valle, J., 21 May 2020, In: Journal of Hepatology. 73, 5, p. 1109-1117

**Scheduling nab-paclitaxel combined with gemcitabine as first line treatment for metastatic pancreatic adenocarcinoma**

Corrie, P. G., Qian, W., Basu, B., Valle, J., Falk, S., Iwuiji, C., Wasan, H., Palmer, D., Scott-Brown, M., Wadsley, J., Arif, S., Bridgewater, J., Propper, D., Gillmore, R., Gopinathan, A., Skells, R., Bundi, P., Brais, R., Dalchau, K. & Bax, L. & 14 others, Chhabra, A., Machin, A., Dayim, A., McAdam, K., Cummins, S., Wall, L., Ellis, R., Anthoney, A., Evans, J., Ma, Y. T., Isherwood, C., Neesse, A., Tuveson, D. & Jodrell, D. I., 30 Apr 2020, In: BJC. 122, p. 1760-1768

**Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives**

Akhoundova Sanoyan, D., Mcnamara, M., Lamarca, A. & Valle, J., 23 Apr 2020, (Accepted/In press) In: Current opinion in oncology.

**THE CLINICAL AND COST-EFFECTIVENESS OF SUPPLEMENTAL PARENTERAL NUTRITION IN ONCOLOGY**

Webb, N., Fricke, J., Trueman, D., Ghosh, S., Winstone, J., Miners, A., Shepelev, J. & Valle, J., 21 Apr 2020, (Accepted/In press) In: ESMO Open.

**NUC-1031/cisplatin vs gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)**

Mcnamara, M., Goyal, L., Doherty, M., Springfield, C., Cosgrove, D., Sjoquist, K. M., Park, J. O., Verdaguer, H., Braconi, C., Ross, P. J., Gramont, A. D., Zalcborg, J. R., Palmer, D. H., Valle, J. & Knox, J. J., 9 Apr 2020, (Accepted/In press) In: Future oncology (London, England).

**Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours**

Chiramel, J., Almond, R., Slagter, A., Khan, A., Wang, X., Lim, K. H. J., Frizziero, M., Lamarca, A., Mansoor, W., Hubner, R., Valle, J. & Mcnamara, M., 9 Apr 2020, (Accepted/In press) In: World Journal of Clinical Oncology.

**The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: in need of a new gold-standard.**

Carnie, L. E., Lamarca, A., Mcnamara, M., Bibby, N., O'Reilly, D. A. & Valle, J., 2 Apr 2020, (E-pub ahead of print) In: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

**Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?**

Kapacee, Z. A., Mcnamara, M. G., De Liguori Carino, N., Lamarca, A., Valle, J. W. & Hubner, R. A., 27 Mar 2020, In: European Journal of Surgical Oncology.

**Safety, tolerability and clinical implementation of 'ready-to-use' (68)gallium-DOTA0-Tyr3-octreotide (Ga-68-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs)**

Manoharan, P., Lamarca, A., Navalkisoor, S., Calero, J., Chan, P. S., Julyan, P. J., Sierra, M. L., Caplin, M. & Valle, J., 17 Mar 2020, In: ESMO Open. 5, 2, e000650.

### **Outcomes in older patients with biliary tract cancer**

Mcnamara, M., de Liguori-Carino, N., Kapacee, Z. A., Lamarca, A. & Valle, J., 13 Mar 2020, In: *European Journal of Surgical Oncology*.

### **Liver embolisation for patients with neuroendocrine neoplasms: systematic review**

Kanabar, R., Barriuso, J., Mcnamara, M., Mansoor, W., Hubner, R., Valle, J. & Lamarca, A., 12 Mar 2020, (Accepted/In press) In: *Neuroendocrinology*.

### **Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis**

Mcnamara, M., Frizziero, M., Jacobs, T., Lamarca, A., Hubner, R., Valle, J. & Eitan, A., 4 Mar 2020, (Accepted/In press) In: *Therapeutic Advances in Medical Oncology*.

### **Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial**

New EPOC investigators, Mar 2020, In: *The Lancet Oncology*. 21, 3, p. 398-411 14 p.

### **TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial**

Palmer, D. H., Valle, J. W., Ting Ma, Y., Faluyi, O., Neoptolemos, J. P., Jensen Gjertsen, T., Iversen, B., Amund Eriksen, J., Møller, A. S., Aksnes, A. K., Miller, R. & Dueland, S., 17 Feb 2020, In: *British Journal of Cancer*.

### **NET-02 trial protocol: A multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)**

Craig, Z., Swain, J., Batman, E., Wadsley, J., Reed, N., Faluyi, O., Cave, J., Rohini, S., Chau, I., Wall, L., Lamarca, A., Hubner, R., Mansoor, W., Sarker, D., Meyer, T., Cairns, D. A., Howard, H., Valle, J. & Mcnamara, M., 5 Feb 2020, In: *BMJ Open*. 10, 2, p. e034527 e034527.

### **The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma**

Malik, A. K., Lamarca, A., Siriwardena, A. K., O'reilly, D., Deshpande, R., Satyadas, T., Jamdar, S., Sheen, A., Mcnamara, M., Hubner, R., Valle, J. & De Liguori Carino, N., 3 Feb 2020, In: *Pancreas*. 49, 2, p. 201-207

### **FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?**

Lamarca, A., Foster, L. & Valle, J., 30 Jan 2020, (Accepted/In press) In: *ESMO Open*.

### **Clinical and translational research challenges in biliary tract cancers**

Lamarca, A., Frizziero, M., Mcnamara, M. & Valle, J., 1 Jan 2020, In: *Current Medicinal Chemistry*.

### **PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer**

Dreyer, S. B., Jamieson, N. B., Cooke, S. L., Valle, J. W., McKay, C. J., Biankin, A. V. & Chang, D. K., Jan 2020, In: *Clinical Oncology*. 32, 1, p. 1-4 4 p.

### **Are outcomes of patients with advanced well-differentiated GEP-NETs on somatostatin analogues similar, irrespective of tracer uptake on 68gallium DOTA SSTR peptide PET CT scans?**

Shah, D., Loveland, O., Chander, A., Westwood, T., Manoharan, P., Mansoor, W., Lamarca, A., Hubner, R. A., Valle, J. & Mcnamara, M., 2020.

### **Chemotherapy – available drugs, mechanisms and toxicity**

Nagy, B., Lamarca, A., Mcnamara, M., Hubner, R. & Valle, J., 2020, *Textbook of Pancreatic Cancer. Principles and Practice of Surgical Oncology* .

### **Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Multinational Study on Risk Factors and Outcomes**

Taboada, R., Riechelmann, R., Mauro, C., Barros, M., Hubner, R., Mcnamara, M., Lamarca, A. & Valle, J., 2020, p. 260.

**Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis**

Frizziero, M., Chakrabarty, B., Nagy, Z., Lamarca, A., Hubner, R. A., Valle, J. & Mcnamara, M., 2020, In: Journal of Clinical Medicine. 9, 1, p. 273

**NUC-1031 in combination with cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)**

Knox, J. J., Mcnamara, M., Goyal, L., Doherty, M., Springfield, C., Oh Park, J., DeGramont, A., Verdaguer, H., Zalberg, J. R., Palmer, D. H., Evans, T. J., Ross, P. J. & Valle, J., 2020.

**Prognostic significance of baseline neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR) and systemic immune-inflammation index (SII) in patients (pts) with biliary tract cancer (BTC)**

Tariq, N.-U.-A., Raja, H., Wang, X., Mehta, S., Lamarca, A., Hubner, R., Mcnamara, M. & Valle, J., 2020.

**Systemic Chemotherapy for Inoperable Goblet Cell Adenocarcinomas (GCAs) and the Role of Anti-EGFR Antibodies**

Barriuso, J., Martin, A., Chakrabarty, B., Burghel, G., Lamarca, A., Kamposioras, K., Mcnamara, M., Clouston, H., Hubner, R., O'Dwyer, S., Wallace, A. & Valle, J., 2020, p. 202.

**Current standards and future perspectives in adjuvant treatment for biliary tract cancers**

Lamarca, A., Edeline, J., Mcnamara, M., Hubner, R., Nagino, M., Bridgewater, J., Primrose, J. & Valle, J., 4 Dec 2019, (E-pub ahead of print) In: Cancer Treatment Reviews.

**Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015**

Valle, J. & et al., 26 Nov 2019, In: BJC. 121, p. 966-972

**Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: Long-term results of the New EPOC randomised clinical trial**

Valle, J., O'Reilly, D., Siriwardena, A. & et al., 16 Nov 2019, (Accepted/In press) In: Lancet Oncology.

**A prospective study of Change in Liver Function and Fat in patients with colorectal liver metastases undergoing pre-operative chemotherapy: protocol for the CLIFF study**

Parmar, K., O'Reilly, D., Valle, J., Braun, M., Naish, J., Williams, S. R., Lloyd, W., Malcomson, L., Cresswell, K., Bamford, C. & Renehan, A., 23 Oct 2019, (Accepted/In press) In: BMJ Open.

**Identification of areas for improvement in the management of bone metastases in patients with neuroendocrine neoplasms**

Lim, K. H. J., Raja, H., D'Arienzo, P., Barriuso, J., Mcnamara, M., Hubner, R., Mansoor, W., Valle, J. & Lamarca, A., 21 Oct 2019, (Accepted/In press) In: Neuroendocrinology.

**A retrospective study on Mixed Neuroendocrine Non-Neuroendocrine Neoplasms from five European centres**

Frizziero, M., Wang, X., Chakrabarty, B., Childs, A., Luong, T. V., Walter, T., Khan, M. S., Morgan, M., Christian, A., Elshafie, M., Shah, T., Minicozzi, A., Mansoor, W., Meyer, T., Lamarca, A., Hubner, R., Valle, J. & Mcnamara, M., 10 Sept 2019, (Accepted/In press) In: World Journal of Gastroenterology.

**A case report of unusual skull base metastasis from neuroendocrine tumour**

Lim, K. H. J., Valle, J. & Lamarca, A., 30 Aug 2019, In: Journal of Medical Case Reports.

**Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer**

Mohan, S., Ayub, M., Rothwell, D., Gulati, S., Kilerci, B., Hollebecque, A., Leong, H. S., Smith, N., Sahoo, S., Descamps, T., Zhou, C., Hubner, R., Mcnamara, M., Lamarca, A., Valle, J. & Dive, C., 12 Aug 2019, In: Scientific Reports.

**Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study**

Carmona-bayonas, A., Jiménez-fonseca, P., Lamarca, Á., Barriuso, J., Castaño, Á., Benavent, M., Alonso, V., Riesco-martínez, M. D. C., Alonso-gordo, T., Custodio, A., Sánchez Cánovas, M., Hernando Cubero, J., López, C., Lacasta, A., Fernández Montes, A., Marazuela, M., Crespo, G., Escudero, P., Diaz, J. Á. & Feliciangeli, E. & 9 others, Gallego, J., Llanos, M., Segura, Á., Vilardell, F., Percovich, J. C., Grande, E., Capdevila, J., Valle, J. W. & García-carbonero, R., 7 Aug 2019, In: Journal of Clinical Oncology. p. JCO.19.00980

**Carboplatin in combination with oral or intravenous etoposide for extra-pulmonary, poorly-differentiated neuroendocrine carcinomas**

Frizziero, M., Spadaro, F., Lamarca, A., Kordatou, Z., Barriuso, J., Nuttall, C., Mcnamara, M., Hubner, R., Mansoor, W., Manoharan, P., Fazio, N. & Valle, J., Aug 2019, In: Neuroendocrinology.

**Systemic Therapy of Gallbladder Cancer: Review of First line, Maintenance, Neoadjuvant and Second line Therapy Specific to Gallbladder Cancer**

Azizi, A. A., Lamarca, A. & Valle, J., 5 Jul 2019, In: Chinese clinical oncology.

**Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials**

Lamarca, A., Ross, P., Wasan, H. S., Hubner, R. A., Mcnamara, M. G., Lopes, A., Manoharan, P., Palmer, D., Bridgewater, J. & Valle, J. W., 11 May 2019, In: Journal National Cancer Institute.

**Medical treatment for cholangiocarcinoma**

Adeva, J., Sangro, B., Salati, M., Edeline, J., La Casta, A., Bittoni, A., Berardi, R., Bruix, J. & Valle, J. W., May 2019, In: Liver International. 39, S1, p. 123-142 20 p.

**Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study**

BILCAP study group, 25 Mar 2019, In: The Lancet Oncology. 20, 5, p. 663-673 11 p.

**Management of bone metastases (BMs) in patients (pts) with neuroendocrine neoplasms (NENs): Findings from a retrospective study.**

Lamarca, A., Lim, J., Raja, H., D'Arienzo, P., Barriuso, J., Mcnamara, M., Hubner, R., Mansoor, W. & Valle, J., 6 Mar 2019, p. 1-273.

**Second-line treatment in patients (pts) with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma (EP-PD-NEC): A systematic review and meta-analysis**

Mcnamara, M., Frizziero, M., Jacobs, T., Lamarca, A., Hubner, R., Valle, J. & Eitan, A., 6 Mar 2019.

**Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis**

Flaum, N., Hubner, R., Valle, J., Amir, E. & Mcnamara, M., 2019, In: Journal of Surgical Oncology .

**Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline**

Kennedy, E. B., Shroff, R. T., Bachini, M., Bekaii-Saab, T., Crane, C., Edeline, J., El-Khoueiry, A., Feng, M., Katz, M. H. G., Primrose, J., Soares, H. P., Valle, J. & Maithel, S. K., 2019, In: Journal of Clinical Oncology. p. JCO1802178

**Anticancer activity in patients with advanced ovarian and biliary tract cancers treated with NUC-1031 and a platinum agent**

Blagden, S., Bre, J., Mullen, P., Gnanaranjan, C., Ghazaly, E., Mcnamara, M. & Valle, J., 2019, p. Abstract 3030.

**Biliary tract cancers: current knowledge, clinical candidates and future challenges**

Tariq, N.-U.-A., Mcnamara, M. & Valle, J., 2019, In: Cancer Management and Research. 2019, 11, p. 2623-2642 20 p.

**Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need**

The ENETS 2016 Munich Advisory Board Participants, 2019, In: Neuroendocrinology. 108, 1, p. 45-53 9 p.

**Evaluation and management of incidental gallbladder cancer**

Zaidi, M. Y., Abou-alfa, G. K., Ethun, C. G., Shrikhande, S. V., Goel, M., Nervi, B., Primrose, J., Valle, J. W. & Maithel, S. K., 2019, In: Chinese clinical oncology. 8, 4, p. 37-37

**Fluorothymidine Positron Emission Tomography (FLT-PET) Repeatability and Response Evaluation in Advanced Pancreatic Cancer Patients Treated with Gemcitabine-Based Chemotherapy**

Lamarca, A., Manoharan, P., Julyan, P., Tamal, M., Rao, M., Cotterill, A., Trigonis, I., Mcnamara, M., Hubner, R., Win, Z., Valle, J. & Saleem, A., 2019, In: *Clinical Oncology and Research*.

**Follow-up recommendations after curative resection of well-differentiated Neuroendocrine Tumours: review of current evidence and clinical practice**

Lamarca, A., Clouston, H., Barriuso, J., Mcnamara, M., Frizziero, M., Mansoor, W., Hubner, R., Manoharan, P., O'Dwyer, S. & Valle, J., 2019, In: *Journal of Clinical Medicine*.

**Hepatic arterial embolisation for patients diagnosed with neuroendocrine neoplasms: experience from a European Neuroendocrine Tumour Society centre of excellence**

Nuttall, C., Lamarca, A., Mcnamara, M., Barriuso, J., Lawrance, J., Mullan, D., Mansoor, W., Valle, J. W. & Hubner, R. A., 2019, p. 6.

**Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice**

Fulton, A. J., Lamarca, A., Nuttall, C., McCallum, L., Pihlak, R., O'Reilly, D., Laloo, F., Mcnamara, M., Hubner, R., Clancy, T. & Valle, J., 2019, In: *World Journal of Gastrointestinal Oncology*. 11, 2, p. 102-116 15 p.

**Impact of anatomic site of biliary tract tumour origin and conditional probability of survival (CS): results from 15 prospective advanced first-line clinical trials**

Mcnamara, M., Lopes, A., Wasan, H., Malka, D., Goldstein, D., Shannon, J., Ojusaka, T., Knox, J. J., Wagner, D., Andre, T., Cunningham, D., Moehler, M., Jensen, L. H., Koeberle, D., Bekaii-Saab, T., Bridgewater, J. & Valle, J., 2019, p. v253-v324.

**Liver embolisation for patients diagnosed with neuroendocrine neoplasms: Systematic review and meta-analysis of the literature**

Kanabar, R., Barriuso, J., Mcnamara, M., Mansoor, W., Hubner, R., Valle, J. W. & Lamarca, A., 2019, p. 14.

**NET-02: A multi-centre, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC)**

Mcnamara, M., Swain, J., Craig, Z., Wadsley, J., Reed, N., Faluyi, O., Lamarca, A., Hubner, R., Mansoor, W., Sarker, D., Howard, H., Cairns, D., Meyer, T. & Valle, J., 2019, p. TPS4158.

**Novel treatments for advanced cholangiocarcinoma**

Cotton, J., Lamarca, A., Mcnamara, M. & Valle, J., 2019, *Liver Cancers*. Cross, T. & Palmer, D. (eds.). Springer Nature, p. 227-243

**NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer**

Knox, J. J., Mcnamara, M., Palmer, D., Evans, T., Goldstein, D., Bridgewater, J. & Valle, J., 2019, p. TPS4156.

**Observational study to assess quality of life in patients with pancreatic neuroendocrine tumours receiving treatment with Everolimus: The OBLIQUE Study (UK Phase IV trial)**

Ramage, J. K., Punia, P., Faluyi, O., Frilling, A., Meyer, T., Saharan, R. & Valle, J., 2019, In: *Neuroendocrinology*.

**Outcomes in patients ≥80 years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy**

Lewis, A. R., Cipriano, C., Wang, X., Ward, R., Fitzpatrick, A., Scott, A. R. M., Rashed, A., Raja, H., Lamarca, A., Hubner, R. A., Valle, J. & Mcnamara, M., 2019, In: *Medical Oncology*.

**Patterns of Recurrence after Resection of Pancreatic Ductal Adenocarcinoma in the ESPAC-4 Randomized Adjuvant Chemotherapy Trial**

Valle, J., O'Reilly, D. & et al., 2019, In: *JAMA Surgery*.

**Prognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: a systematic review and meta-analysis**

Mcnamara, M., Jacobs, T., Frizziero, M., Pihlak, R., Lamarca, A., Hubner, R., Valle, J. & Amir, E., 2019, p. v25-v54.

**Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhoea: patient selection and reported outcomes**

Saavedra, C., Barriuso, J., Mcnamara, M., Valle, J. & Lamarca, A., 2019, In: Cancer Management and Research.

**Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data**

Valle, J. W., Borbath, I., Rosbrook, B., Fernandez, K. & Raymond, E., 2019, In: Future oncology (London, England).

**<sup>18</sup>F-fluorodeoxyglucose positron emission tomography ( <sup>18</sup> FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis**

Lamarca, A., Barriuso, J., Chander, A., Mcnamara, M., Hubner, R., O'Reilly, D., Manoharan, P. & Valle, J., 2019, In: Journal of Hepatology.

**Systemic chemotherapy for inoperable Goblet Cell Adenocarcinomas (GCAs)**

Barriuso, J., Lamarca, A., Martin, A., Chakrabarty, B., Clouston, H., Mullanitha, S., Mcnamara, M., Marti-Marti, F., Hubner, R., Saunders, M., O'Dwyer, S., Braun, M. & Valle, J. W., 2019, p. 12.

**Temozolomide-Capcitabine (TemCap) chemotherapy for Neuroendocrine Neoplasms (NENs): the dilemma of treatment duration**

Lamarca, A., Barriuso, J., Mcnamara, M. G., Hubner, R. A., Manoharan, P., Mansoor, W. & Valle, J. W., 2019, In: Neuroendocrinology.

**Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms**

The ENETS 2016 Munich Advisory Board Participants, 2019, In: Neuroendocrinology. 108, 1, p. 7-17 11 p.

**Bone metastases (BMs) in patients with neuroendocrine neoplasms (NENs): Prevalence and clinical management in a tertiary cancer centre**

Lim, J., Raja, H., Paolo, D., Barriuso, J., Mcnamara, M., Hubner, R., Mansoor, W., Valle, J. & Lamarca, A., Dec 2018.

**Second primary malignancies (SPMs) in patients with non-pulmonary well-differentiated neuroendocrine tumours (wdNETs)**

Dafnis, A., Raja, H., Chakrabarty, B., Lamarca, A., Hubner, R., Mansoor, W., Valle, J. & Mcnamara, M., Dec 2018.

**Sorafenib as first-line therapy in patients with advanced Child-Pugh B Hepatocellular Carcinoma – a meta-analysis**

Mcnamara, M., Slagter, A. E., Nuttall, C., Frizziero, M., Pihlak, R., Lamarca, A., Tariq, N.-U.-A., Valle, J., Hubner, R., Knox, J. J. & Amir, E., Dec 2018, In: European Journal of Cancer. 105

**Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison**

Ishak, K. J., Rael, M., Hicks, M., Mittal, S., Eatock, M. & Valle, J. W., Oct 2018, In: Journal of Comparative Effectiveness Research. 7, 10, p. 947-958

**Biliary Tract Cancer: State of the Art and promising targeted therapies under development**

Lamarca, A., Barriuso, J., Mcnamara, M. & Valle, J., 6 Sept 2018, (Accepted/In press) In: Cancer Treatment Reviews.

**PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer**

Pereira, S. P., Jitlal, M., Duggan, M., Lawrie, E., Beare, S., O'Donoghue, P., Wasan, H. S., Valle, J. W. & Bridgewater, J., 23 Jul 2018, In: ESMO Open. 3, 5, p. e000379

**Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial**

Backen, A., Lopes, A., Wasan, H., Palmer, D. H., Duggan, M., Cunningham, D., Anthoney, A., Corrie, P. G., Madhusudan, S., Maraveyas, A., Ross, P. J., Waters, J. S., Steward, W. P., Rees, C., Mcnamara, M., Beare, S., Bridgewater, J. A., Dive, C. & Valle, J., 21 Jun 2018, In: British Journal of Cancer. 119

**Biliary tract cancer: Implicated immune-mediated pathways and their associated potential targets.**

Tariq, N.-U.-A., Vogel, A., Mcnamara, M. & Valle, J., 1 May 2018, In: Oncology Research and Treatment. 41, 5, p. 298-304 7 p.

**Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary**

Singh, S., Carnaghi, C., Buzzoni, R., Pommier, R. F., Raderer, M., Tomasek, J., Lahner, H., Valle, J. W., Voi, M., Bubuteishvili-pacaud, L., Lincy, J., Wolin, E., Okita, N., Libutti, S. K., Oh, D.-Y., Kulke, M., Strosberg, J., Yao, J. C., Pavel, M. E. & Fazio, N., 1 Apr 2018, In: Neuroendocrinology. 106, 3, p. 211-220

**PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours.**

Lamarca, A., Nonaka, D., Breitwieser, W., Ashton, G., Barriuso, J., Mcnamara, M., Moghadam, S., Rogan, J., Mansoor, W., Hubner, R. A., Clark, C., Chakrabarty, B. & Valle, J., 13 Mar 2018, In: Oncotarget. p. 14922-14938 16 p.

**Carboplatin-Etoposide Chemotherapy (CB-ET) for Patients Diagnosed with Advanced Extra-Pulmonary (EP) Poorly Differentiated (PD) Neuroendocrine Carcinoma (NEC): Findings from a European Neuroendocrine Tumor Society Centre of Excellence**

Frizziero, M., Lamarca, A., Kordatou, Z., Barriuso, J., Nuttall, C., Mcnamara, M., Hubner, R., Mansoor, W., Manoharan, P. & Valle, J., 9 Mar 2018.

**International Survey of Clinical Practice Exploring Use of Platinum-Etoposide Chemotherapy for Extra-Pulmonary High Grade Neuroendocrine Carcinoma (EP-G3-NEC)**

Lamarca, A., Frizziero, M., Barriuso, J., Mcnamara, M., Hubner, R. & Valle, J., 9 Mar 2018.

**A study of appendiceal crypt cell adenocarcinoma (so-called goblet cell carcinoid and its related adenocarcinoma)**

Nonaka, D., Papaxoinis, G., Lamarca, A., Fulford, P., Valle, J. & Chakrabarty, B., Feb 2018, In: Human Pathology. 72, p. 18-27 10 p.

**Advances in molecular profiling and categorisation of pancreatic adenocarcinoma and the implications for therapy**

Pihlak, R., Weaver, J. M., Valle, J. & Mcnamara, M., 2018, In: Cancers. 10, 1

**Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome**

Weickert, M. O., Kaltsas, G., Hörsch, D., Lapuerta, P., Pavel, M., Valle, J., Caplin, M. E., Bergsland, E., Kunz, P. L., Anthony, L. B., Grande, E., Öberg, K., Welin, S., Lombard-Bohas, C., Ramage, J. K., Kittur, A., Yang, Q. & Kulke, M. H., 2018, In: Clinical Therapeutics.

**Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.**

Elander, N. O., Augthton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D., Cox, T. F., Campbell, F., Costello, E., Halloran, C., Mackey, J., Scarfe, A. G., Valle, J., McDonald, A., Carter, R., Tebbutt, N., Goldstein, D., Shannon, J., Dervenis, C., Glimelius, B. & Deakin, M. & 7 others, Charnley, R., Anthoney, A., Lerch, M., Mayerle, J., Olah, A., Buchler, M. & Greenhalf, W., 2018, In: British Journal of Cancer. 118, p. 947-954 7 p.

**Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours**

Lewis, A., Wang, X., Magdalani, L., D'Arienzo, P., Bashir, C., Mansoor, W., Hubner, R., Valle, J. & Mcnamara, M., 2018, In: World Journal of Gastroenterology.

**Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe**

Javed, M. A., Beyer, G., Le, N., Vinci, A., Wong, H., Palmer, D., Morgan, R. D., Lamarca, A., Hubner, R. A., Valle, J. W., Alam, S., Chowdhury, S., Ma, Y. T., Archibugi, L., Capurso, G., Maisonneuve, P., Neesse, A., Sund, M., Schober, M. & Krug, S., 2018, In: Pancreatology.



**Intratumoural expression of deoxycytidylate deaminase or ribonucleotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy**

Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Campbell, F., Costello, E., Halloran, C. M., Mackey, J. R., Scarfe, A. G., Valle, J. W., McDonald, A. C., Carter, R., Tebbutt, N. C., Goldstein, D., Shannon, J., Dervenis, C., Glimelius, B. & Deakin, M. & 7 others, Charnley, R. M., Anthoney, A., Lerch, M. M., Mayerle, J., Oláh, A., Büchler, M. W. & Greenhalf, W., 2018, In: British Journal of Cancer. 118, 8, p. 1084-1088 5 p.

**Irreversible electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?**

de Liguori-Carino, N., O'Reilly, D., Siriwardena, A., Valle, J., Radhakrishna, G., Pihlak, R. & Mcnamara, M., 2018, In: European Journal of Surgical Oncology.

**Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study**

Lamarca, A., McCallum, L., Nuttall, C., Barriuso, J., Backen, A., Frizziero, M., Leon, R., Mansoor, W., Mcnamara, M. G., Hubner, R. A. & Valle, J. W., 2018, In: Expert Review of gastroenterology and Hepatology. 12, 7, p. 723-731

**The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers**

Lamarca, A., Galdy, S., Barriuso, J., Moghadam, S., Beckett, E., Rogan, J., Backen, A., Billington, C., Mcnamara, M., Hubner, R., Cramer, A. & Valle, J., 2018, In: P L o S One. 13, 10, e0206007.

**Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC)**

Lamarca, A., Frizziero, M., Barriuso, J., Mcnamara, M. G., Hubner, R. A. & Valle, J. W., 2018, In: Clinical and Translational Oncology.

**Outcomes in patients aged  $\geq 80$  years with Hepatopancreaticobiliary (HPB) malignancies**

Lewis, A., Cipriano, C., Wang, X., Lamarca, A., Hubner, R., Valle, J. & Mcnamara, M., Nov 2017.

**Experience in Managing Patients with Carcinoid Syndrome from A European Neuroendocrine Tumour Society Centre Of Excellence**

d'Arienzo, P., Amir, E., Lewis, A., Magdalani, L., Hubner, R., Valle, J. & Mcnamara, M., 24 Oct 2017, In: European Medical Journal Oncology. 5, 1, 2 p.

**The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma**

European Study Group for Pancreatic Cancer, 24 Oct 2017, (E-pub ahead of print) In: Annals of surgery.

**Carcinoid syndrome: Patient outcomes from a European Neuroendocrine Tumour Society (ENETs) centre of excellence**

d'Arienzo, P., Amir, E., Lewis, A. R., Magdalani, L., Mansoor, W., Hubner, R., Valle, J. & Mcnamara, M., Sept 2017.

**HER-2/HER-3 pathway as a potentially-actionable target in biliary tract cancers (BTCs): A retrospective analysis**

Lamarca, A., Galdy, S., Moghadam, S., Rogan, J., Mcnamara, M., Hubner, R., Cramer, A. & Valle, J., Sept 2017.

**Mixed adeno-neuroendocrine carcinoma (MANEC) of the gastroenteropancreatic (GEP) tract: A multicentre retrospective study**

Frizziero, M., Wang, X., Chakrabarty, B., Childs, A., Luong, T., Walter, T., Elshafie, M., Shah, T., Fulford, P., Minicozzi, A., Mansoor, W., Meyer, T., Hubner, R., Valle, J. & Mcnamara, M., Sept 2017.

**Pancreatic exocrine insufficiency (PEI) in patients (pts) with well-differentiated neuroendocrine tumours (wd-NETs) treated with somatostatin analogues (SSAs): Incidence and impact on quality of life**

Lamarca, A., McCallum, L., Nuttall, C., Barriuso, J., Frizziero, M., Leon, R., Mansoor, W., Mcnamara, M., Hubner, R. & Valle, J., Sept 2017.

**Temozolomide-capecitabine (TemCap) chemotherapy for neuroendocrine neoplasms (NENs): Time to maximum response and optimal treatment duration**

Lamarca, A., Barriuso, J., McCallum, L., Papaxoinis, G., Nasralla, M., Nuttall, C., Frizziero, M., Kordatou, Z., Mcnamara, M., Hubner, R. A., Manoharan, P., Mansoor, W. & Valle, J., Sept 2017.

**New Horizons for Precision Medicine in Biliary Tract Cancers**

Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J. & Zhu, A. X., Aug 2017, In: Cancer discovery. 7, 9, p. 943-962 20 p.

**The dark side of T1 non-appendiceal small bowel neuroendocrine tumors**

Salih, Z., Lamarca, A., Nonaka, D., Hubner, R. A., de Liguori-Carino, N., McNamara, M. G., Fulford, P., Minicozzi, A., O'Dwyer, S., Chakrabarty, B. & Valle, J. W., Aug 2017, In: Human Pathology. 66, p. 239-240 2 p.

**Circulating Tumour Cells**

Georgiadis, K., Simpson, K., Ayub, M., Brady, G., Valle, J., Jorgensen, C. & Dive, C., 5 Jul 2017, (Accepted/In press) *Pancreatic Cancer*. Springer Nature

**Adjuvant chemotherapy and outcome in patients (pts) with nodal (N-) and resection margin negative (R0) pancreatic adenocarcinoma (PC): A systematic review and meta-analysis**

Flaum, N., Hubner, R., Valle, J., Amir, E. & Mcnamara, M., 3 Jun 2017.

**Inter-tumor validation, through advanced MRI and circulating biomarkers, of plasma Tie2 as the vascular response biomarker for bevacizumab.**

Jayson, G. C., Zhou, C., Horsley, L. H., Marti, K., Shaw, D., Mescallado, N., Clamp, A. R., Saunders, M. P., Valle, J. W., Backen, A. C., Simpson, K., Little, R., Watson, Y., Cheung, S., Roberts, C., Manoharan, P., Jackson, A., O'Connor, J., Parker, G. J. M. & Dive, C., 20 May 2017, In: Journal of Clinical Oncology. 35

**Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours**

Lepage, C., Dahan, L., Bouarioua, N., Toumpanakis, C., Legoux, J.-L., Le Malicot, K., Guimbaud, R., Smith, D., Tougeron, D., Lievre, A., Cadiot, G., Di Fiore, F., Bouhier-Leporrier, K., Hentic, O., Faroux, R., Pavel, M., Borbath, I., Valle, J. W., Rinke, A. & Scoazec, J.-Y. & 2 others, Ducreux, M. & Walter, T., 1 May 2017, In: Digestive and Liver Disease. 49, 5, p. 568-571 4 p.

**Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours**

Clay, V., Papaxoinis, G., Sanderson, B., Valle, J. W., Howell, M., Lamarca, A., Krysiak, P., Bishop, P., Nonaka, D. & Mansoor, W., 1 May 2017, In: Clinical and Translational Oncology. 19, 5, p. 579-586 8 p.

**Germline mutations in pancreatic cancer and potential new therapeutic options**

Pihlak, R., Valle, J. & Mcnamara, M., 20 Apr 2017, In: Oncotarget.

**HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: A potential therapeutic target?**

Galdy, S., Lamarca, A., Mcnamara, M., Hubner, R., Cella, C. A., Fazio, N. & Valle, J., Mar 2017, In: Cancer and Metastasis Reviews. 36, 1, p. 141-157 17 p.

**Mixed Adeno-Neuroendocrine Carcinoma (MANEC) of the Gastrointestinal (GI) Tract: Experience of a European Neuroendocrine Tumour Society (ENETS) Centre of Excellence**

Frizziero, M., Wang, X., Chakrabarty, B., Mansoor, W., Fulford, P., Hubner, R., Valle, J. & Mcnamara, M., Mar 2017, p. 1. 338 p.

**PD-1, PD-L1 and PD-L2 Expression in Well-Differentiated Small Bowel Gastrointestinal Neuroendocrine Tumours (Wd SB-NETs)**

Lamarca, A., Nonaka, D., Breitwieser, W., Ashton, G., Barriuso, J., Moghadam, S., Mcnamara, M., Mansoor, W., Hubner, R., Clark, C., Chakrabarty, B. & Valle, J., Mar 2017.

### **The dark side of T1 non-appendiceal small bowel neuroendocrine tumours**

Salih, Z., Lamarca, A., Nonaka, D., Hubner, R., de Liguori-Carino, N., Mcnamara, M., Fulford, P., Minicozzi, A., O'Dwyer, S., Chakrabarty, B. & Valle, J., 24 Feb 2017, (Accepted/In press) In: Human Pathology.

### **Elderly patients diagnosed with hepatopancreatobiliary malignancies: A challenge beyond resection**

Lamarca, A., Pihlak, R., Frizziero, M., McNamara, M. G., Hubner, R. A. & Valle, J. W., 21 Feb 2017, In: Cancer. 123, 5, p. 888-890 3 p.

### **Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients with High-Grade Gastrointestinal Neuroendocrine Carcinomas**

Lamarca, A., Walter, T., Pavel, M. E., Ivan, B., Freis, P., Nunez, B., Alexa, C., Mcnamara, M., Hubner, R., Garcia-Carbonero, R., Tim, M., Valle, J. & Barriuso, J., 27 Jan 2017, In: Journal of the National Cancer Institute. 109, 5, djw277.

### **Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.**

European Study Group for Pancreatic Cancer, 25 Jan 2017, In: The Lancet. 389, 10073, p. 1011-1024

### **Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome**

Kulke, M. H., Hörsch, D., Caplin, M. E., Anthony, L. B., Bergsland, E., Öberg, K., Welin, S., Warner, R. R. P., Lombard-Bohas, C., Kunz, P. L., Grande, E., Valle, J. W., Fleming, D., Lapuerta, P., Banks, P., Jackson, S., Zambrowicz, B., Sands, A. T. & Pavel, M., 1 Jan 2017, In: Journal of Clinical Oncology. 35, 1, p. 14-23 10 p.

### **Current Status on Cholangiocarcinoma and Gallbladder Cancer**

Ebata, T., Ercolani, G., Alvaro, D., Ribero, D., Di Tommaso, L. & Valle, J. W., Jan 2017, In: Liver Cancer. 6, 1, p. 59-65 7 p.

### **68Gallium DOTANOC-PET imaging in Lung Carcinoids: impact on patients' management**

Lamarca, A., Pritchard, D. M., Westwood, T., Papaxoinis, G., Nonaka, D., Vinjamuri, S., Valle, J., Manoharan, P. & Mansoor, W., 2017, In: Neuroendocrinology.

### **A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial**

Kulke, M. H., Ruszniewski, P., Van Cutsem, E., Lombard-Bohas, C., Valle, J., De Herder, W. W., Pavel, M., Degtyareva, E., Brase, J. C., Pacaud, L. B., Voi, M., Salazar, R., Borbath, I., Fazio, N., Smith, D., Capdevila, J., Riechelmann, R. P. & Yao, J. C., 2017, In: Annals of Oncology. 28, 6, mdx078.

### **Carboplatin-etoposide chemotherapy for patients with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); outcomes from a European Neuroendocrine Tumour Society Centre of Excellence**

Frizziero, M., Lamarca, A., Kordatou, Z., Barriuso, J., Nuttall, C., Mcnamara, M., Hubner, R. A., Mansoor, W., Manoharan, P. & Valle, J., 2017, p. 21.

### **Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response**

Lamarca, A., Barriuso, J., Kulke, M. H., Ivan, B., Lenz, H.-J., Raoul, J.-L., Meropol, N. J., Lombard-Bohas, C., Posey, J., Faivre, S., Raymond, E. & Valle, J., 2017, In: British Journal of Cancer.

### **ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents**

Antibes Consensus Conference participants, 2017, In: Neuroendocrinology.

### **ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy**

Antibes Consensus Conference participants, 2017, In: Neuroendocrinology.

**ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging**

Antibes Consensus Conference participants, 2017, In: Neuroendocrinology.

**Everolimus in advanced, progressive, well-differentiated, nonfunctional neuroendocrine tumors: RADIANT-4 lung subgroup analysis**

Fazio, N., Buzzoni, R., Fave, G. D., Tesselaar, M., Wolin, E., Cutsem, E. V., Tomassetti, P., Strosberg, J., Voi, M., Pacaud, L. B., Ridolfi, A., Herbst, F., Tomasek, J., Singh, S., Pavel, M., Kulke, M. H., Valle, J. & Yao, J. C., 2017, In: Cancer Science.

**Health-related quality of life in patients with advanced, nonfunctional, well-differentiated gastrointestinal or lung neuroendocrine tumors with everolimus vs. placebo in the phase 3, randomized, RADIANT-4 trial**

Pavel, M. E., Singh, S., Strosberg, J., Pacaud, L. B., Degtyarev, E., Neary, M., Carnaghi, C., Tomasek, J., Wolin, E., Raderer, M., Lahner, H., Valle, J., Pommier, R., Cutsem, E. V., Tesselaar, M. E. T., Fave, G. D., Buzzoni, R., Hunger, M., Eriksson, J. & Cella, D. & 4 others, Ricci, J.-F., Fazio, N., Kulke, M. H. & Yao, J. C., 2017, In: The Lancet Oncology.

**Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4**

Buzzoni, R., Carnaghi, C., Strosberg, J., Fazio, N., Singh, S., Herbst, F., Ridolfi, A., Pavel, M. E., Wolin, E., Valle, J., Oh, D.-Y., Yao, J. C. & Pommier, R., 2017, In: OncoTargets and Therapy.

**New molecular and immunotherapeutic approaches in biliary cancer**

Goldstein, D., Lemech, C. & Valle, J., 2017, In: ESMO Open. 2, Suppl 1, p. e000152

**Sunitinib in Pancreatic Neuroendocrine Tumors: Updated Progression-Free Survival and Final Overall Survival From a Phase III Randomized Study**

Faivre, S., Niccoli, P., Castellano, D., Valle, J. W., Hammel, P., Raoul, J.-L., Vinik, A., Van Cutsem, E., Bang, Y.-J., Lee, S.-H., Borbath, I., Lombard-Bohas, C., Metrakos, P., Smith, D., Chen, J.-S., Ruszniewski, P., Seitz, J.-F., Patyna, S., Lu, D. R. & Ishak, K. J. & 1 others, Raymond, E., 2017, In: Annals of Oncology.

**Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials**

Mcnamara, M., Bridgewater, J., Lopes, A., Wasan, H., Malka, D., Jensen, H., Okusaka, T., Knox, J. J., Wagner, D., Cunningham, D., Shannon, J., Goldstein, D., Moehler, M., Bekaii-Saab, T. & Valle, J., 2017, In: BMC Cancer. 17, 262

**Targeting the epidermal growth factor receptor in addition to chemotherapy in patients with advanced pancreatic cancer: a systematic review and meta-analysis**

Chiramel, J., Backen, A., Pihlak, R., Lamarca, A., Frizziero, M., Tariq, N.-U.-A., Hubner, R. A., Valle, J., Amir, E. & Mcnamara, M., 2017, In: International Journal of Molecular Sciences. 18, 5, 909.

**The clinical efficacy of first generation carcinoembryonic antigen (CEACAM5) specific CAR T cells is limited by poor persistence and transient pre-conditioning dependent respiratory toxicity**

Thistlethwaite, F., Gilham, D., Guest, R., Rothwell, D., Pillai, M., Burt, D., Byatte, A. J., Kirillova, N., Valle, J., Sharma, S. K., Chester, K. A., Westwood, N., Halford, S. E., Nabarro, S., Wan, S., Austin, E. & Hawkins, R. E., 2017, In: Cancer Immunology, Immunotherapy.

**Update on Treatment Options for Advanced Bile Duct Tumours: radioembolisation for advanced cholangiocarcinoma**

Najran, P., Lamarca, A., Mullan, D., Mcnamara, M., Westwood, T., Hubner, R., Lawrence, J., Manoharan, P., Bell, J. & Valle, J., 2017, In: Current Oncology Reports.

**Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (VIP): a prospective, randomised, double-blind, multicentre phase 2 trial**

Middleton, G., Palmer, D. H., Greenhalf, W., Ghaneh, P., Jackson, R., Cox, T., Evans, A. G., Shaw, V. E., Wadsley, J., Valle, J., Propper, D., Wasan, H., Falk, S., Cunningham, D., Coxon, F. Y., Ross, R. P., Madhusudan, S., Wadd, N., Corrie, P. & Hickish, T. & 4 others, Costello, E., Campbell, F., Rawcliffe, C. L. & Neoptolemos, J., 2017, In: The Lancet Oncology. 18, 4, p. 486-499 14 p.

**Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference**  
Abou-Alfa, G. K., Andersen, J. B., Chapman, W., Choti, M., Forbes, S. J., Gores, G. J., Hong, T. S., Harding, J. J., Vander Heiden, M. G., Javle, M., Kelley, R. K., Kwong, L. N., Lowery, M., Merrell, A., Miyabe, K., Rhim, A., Saha, S., Sia, D., Tanasanvimon, S. & Venook, A. & 7 others, Valle, J. W., Walesky, C., Whetstine, J., Willenbring, H., Zhu, A. X., Mayer, D. & Stanger, B. Z., Dec 2016, In: *Journal of Gastrointestinal Oncology*. 7, 6, p. 819-827 9 p.

**Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial**

Vinik, A., Bottomley, A., Korytowsky, B., Bang, Y.-J., Raoul, J.-L., Valle, J. W., Metrakos, P., Hörsch, D., Mundayat, R., Reisman, A., Wang, Z., Chao, R. C. & Raymond, E., Dec 2016, In: *Targeted Oncology*. 11, 6, p. 815-824 10 p.

**Telotristat etiprate: a new option for the management of carcinoid syndrome**

Lamarca, A., Barriuso, J., Mcnamara, M., Hubner, R. & Valle, J., 16 Nov 2016, In: *Expert opinion on pharmacotherapy*.

**Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems**

Flaum, N., Valle, J., Mansoor, W. & Mcnamara, M., Nov 2016, In: *Future Oncology*. 12, 22, p. 2561-2578 18 p.

**Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder**

Kaupp-Roberts, S. D., Yadegarfar, G., Friend, E., O'Donnell, C. M., Valle, J. W., Byrne, C., Bahar, I., Finch-Jones, M., Gillmore, R., Johnson, C. D., Pereira, S. P., Wiggers, J. K., Pinto, M., Al-Sarireh, B. & Ramage, J. K., 25 Oct 2016, In: *British Journal of Cancer*. 115, 9, p. 1032-1038 7 p.

**Prevalence of symptomatic pancreatic exocrine insufficiency in patients with pancreatic malignancy: nutritional intervention may improve survival**

Valle, J., McCallum, L. & Lamarca, A., 16 Sept 2016, In: *Cancer Research Frontiers*. p. 352-367 16 p., 3.

**Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery**

Slagter, A., Ryder, D., Chakrabarty, B., Lamarca, A., Hubner, R., Mansoor, W., O'Reilly, D., Fulford, P., Klümpen, H., Valle, J. & Mcnamara, M., 1 Sept 2016, In: *Surgical Oncology*. 25, 3, p. 223-228 6 p.

**Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up**

Valle, J. W., Borbath, I., Khan, S. A., Huguet, F., Gruenberger, T., Arnold, D. & ESMO Guidelines Committee, Sept 2016, In: *Annals of Oncology*. 27, suppl 5, p. v28-v37

**Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study**

Pugh, S. A., Bowers, M., Ball, A., Falk, S., Finch-Jones, M., Valle, J. W., O'Reilly, D. A., Siriwardena, A. K., Hornbuckle, J., Rees, M., Rees, C., Iveson, T., Hickish, T., Maishman, T., Stanton, L., Dixon, E., Corkhill, A., Radford, M., Garden, O. J. & Cunningham, D. & 3 others, Maughan, T. S., Bridgewater, J. A. & Primrose, J. N., 9 Aug 2016, In: *British Journal of Cancer*. 115, 4, p. 420-4 5 p.

**Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy.**

Lamarca, A., Rigby, C., Mcnamara, M., Hubner, R. & Valle, J., 14 Jul 2016, In: *World Journal of Gastroenterology*. 22, 26, p. 6065-6075

**Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours**

Childs, A., Kirkwood, A., Edeline, J., Luong, T. V., Watkins, J., Lamarca, A., Alrifai, D., Nsiah-Sarbeng, P., Gillmore, R., Mayer, A., Thirlwell, C., Sarker, D., Valle, J. W. & Meyer, T., Jul 2016, In: *Endocrine-related cancer*. 23, 7, p. 563-70 8 p.

**Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients with High-Grade Gastrointestinal Neuroendocrine Carcinomas**

Lamarca, A., Thomas, W., Pavel, M. E., Ivan, B., P, F., B, N., Alexa, C., Mcnamara, M., Hubner, R., R, G.-C., Tim, M., Barriuso, J. & Valle, J., Jun 2016, *Supplement to Journal of Clinical Oncology*. 4089 ed. *Journal of Clinical Oncology*, Vol. 34.

**Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study**  
Ruszniewski, P., Valle, J. W., Lombard-Bohas, C., Cuthbertson, D. J., Perros, P., Holubec, L., Delle Fave, G., Smith, D., Niccoli, P., Maisonobe, P., Atlan, P., Caplin, M. E. & SYMNET study group, May 2016, In: Digestive and Liver Disease. 48, 5, p. 552-8 7 p.

**Quality of life, long-term survivors and long-term outcome from the ABC-02 study**

Bridgewater, J., Lopes, A., Palmer, D., Cunningham, D., Anthony, A., Maraveyas, A., Madhusudan, S., Iveson, T., Valle, J. & Wasan, H., 26 Apr 2016, In: British Journal of Cancer. 114, 9, p. 965-71 7 p.

**Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study**

Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., Tomasek, J., Raderer, M., Lahner, H., Voi, M., Pacaud, L. B., Rouyre, N., Sachs, C., Valle, J. W., Delle Fave, G., Van Cutsem, E., Tessaar, M., Shimada, Y., Oh, D.-Y. & Strosberg, J. & 3 others, Kulke, M. H., Pavel, M. E. & RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group, 5 Mar 2016, In: The Lancet. 387, 10022, p. 968-77 10 p.

**18F-FLT PET imaging of cellular proliferation in pancreatic cancer**

Lamarca, A., Asselin, M.-C., Manoharan, P., Mcnamara, M., Trigonis, I., Hubner, R., Saleem, A. & Valle, J., Mar 2016, In: Critical Reviews in Oncology / Hematology. 99, p. 158-69 12 p.

**Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?**

Lamarca, A., Elliott, E., Barriuso, J., Backen, A., McNamara, M. G., Hubner, R. & Valle, J. W., Mar 2016, In: Cancer Treatment Reviews. 44, p. 26-41 16 p.

**Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours**

Monaghan, P. J., Lamarca, A., Valle, J. W., Hubner, R. A., Mansoor, W., Trainer, P. J. & Darby, D., Mar 2016, In: Clin Endocrinol (Oxf). 84, 3, p. 348-52 5 p.

**Safety and compliance of capecitabine and temozolomide in patients with advanced neuroendocrine tumours.**

Papaxoinin, G., McCallum, L., Nasralla, M., Hubner, R., Mcnamara, M., Valle, J. & Mansoor, W., Mar 2016, p. 71-71. 1 p.

**To Evaluate How the Outcome of Neuroendocrine Tumour (NET) Multidisciplinary Team (MDT) Meeting Decisions Are Conveyed to Patients at a ENETS Centre of Excellence (The Christie) and How This Service Can Be Further Improved**  
Rigby, C., Mansoor, W., Valle, J., Hubner, R. & Mcnamara, M., Mar 2016, *Neuroendocrinology*. Vol. 103. p. 119-119 1 p.

**A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study**

Bridgewater, J., Lopes, A., Beare, S., Duggan, M., Lee, D., Ricamara, M., McEntee, D., Sukumaran, A., Wasan, H. & Valle, J. W., 24 Feb 2016, In: BMC Cancer. 16, 369

**"If You Prick Us, Do We Not Bleed?" Whom Should We Choose?**

McNamara, M. G., Lamarca, A., Hubner, R. A. & Valle, J. W., 4 Jan 2016, In: Journal of Clinical Oncology. 34, 5, p. 513-4 2 p.

**Prognostic factors for progression-free and overall survival in advanced biliary tract cancer**

Bridgewater, J., Lopes, A., Wasan, H., Malka, D., Jensen, L., Okusaka, T., Knox, J., Wagner, D., Cunningham, D., Shannon, J., Goldstein, D., Moehler, M., Bekaii-Saab, T., McNamara, M. G. & Valle, J. W., 1 Jan 2016, In: Annals of Oncology. 27, 1, p. 134-140 7 p.

**Health-related quality of life (HRQoL), anxiety, depression and impulsivity in patients with advanced Gastroenteropancreatic Neuroendocrine Tumours (GEPNETs)**

Lewis, A., Wang, X., Magdalani, L., Bashir, C., Mansoor, W., Hubner, R. A., Valle, J. & Mcnamara, M., 2016.

**Pancreatic Cancer: are "liquid biopsies" ready for prime-time?**

Lewis, A., Valle, J. & Mcnamara, M., 2016, In: World Journal of Gastroenterology. 22, 32, p. 7175-7185 11 p.

**Whole-exome sequencing (WES) of samples from patients with advanced pancreatic neuroendocrine tumours (pNETs) with exceptional responses vs. poor responders to targeted therapies; a TransNET study**

Barriuso, J., Lamarca, A., Mcnamara, M., Burgis, T., Manoharan, P., Hayes, A., Mansoor, W., Hubner, R. & Valle, J., 2016

**Development of a circulating miRNA assay to monitor tumor burden: From mouse to man.**

Greystoke, A., Ayub, M., Rothwell, D. G., Morris, D., Burt, D., Hodgkinson, C. L., Morrow, C. J., Smith, N., Aung, K., Valle, J., Carter, L., Blackhall, F., Dive, C. & Brady, G., 28 Oct 2015, In: Molecular Oncology.

**Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.**

Valle, J. W., Wasan, H., Lopes, A., Backen, A. C., Palmer, D. H., Morris, K., Duggan, M., Cunningham, D., Anthony, D. A., Corrie, P., Madhusudan, S., Maraveyas, A., Ross, P. J., Waters, J. S., Steward, W. P., Rees, C., Beare, S., Dive, C. & Bridgewater, J. A., Aug 2015, In: The Lancet. Oncology. 16, 8, p. 967-78 888 p.

**To BRCA or not to PALB**

Mcnamara, M., Lamarca, A., Hubner, R. & Valle, J., 29 Jun 2015, In: J Clin Oncol. 33, 23, p. 2581-2 2578 p.

**Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer**

Krebs, M. G., Renehan, A. G., Backen, A., Gollins, S., Chau, I., Hasan, J., Valle, J. W., Morris, K., Beech, J., Ashcroft, L., Saunders, M. P. & Dive, C., Jun 2015, In: Clinical Colorectal Cancer. 14, 2

**Appendiceal Goblet Cell Carcinoids: Management Considerations from a Reference Peritoneal Tumour Service Centre and ENETS Centre of Excellence**

Lamarca, A., Nonaka, D., Lopez Escola, C., Hubner, R. A., O'Dwyer, S., Chakrabarty, B., Fulford, P. & Valle, J. W., 2015, In: Neuroendocrinology.

**A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs**

Carrato, A., Falcone, A., Ducreux, M., Valle, J. W., Parnaby, A., Djazouli, K., Alnwick-Allu, K., Hutchings, A., Palaska, C. & Parthenaki, I., 2015, In: Journal of Gastrointestinal Cancer . 46, 3, p. 201-11 189 p.

**Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases**

Primrose, J. N., Cunningham, D., Garden, O. J., Maughan, T. S., Pugh, S. A., Stanton, L., Falk, S. J., Rees, M., Finch-Jones, M., Valle, J. W., O'Reilly, D., Hornbuckle, J., Hickish, T. & Bridgewater, J. A., 2015, In: J Clin Oncol. 33, 21, p. 2405-6 2398 p.

**Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease**

Lamarca, A., Benafif, S., Ross, P., Bridgewater, J. & Valle, J. W., 2015, In: Eur J Cancer. 51, 13, p. 1694-703 990 p.

**Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer**

Grunnet, M., Christensen, I. J., Lassen, U., Jensen, L. H., Lydolph, M., Knox, J. J., McNamara, M. G., Jitel, M., Wasan, H., Bridgewater, J., Valle, J. W. & Mau-Sorensen, M., 2015, In: Eur J Cancer. 51, 11, p. 1381-8 1372 p.

**Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies**

Grenader, T., Nash, S., Plotkin, Y., Furuse, J., Mizuno, N., Okusaka, T., Wasan, H., Valle, J. & Bridgewater, J., 2015, In: Annals of Oncology. 26, 9, p. 1910-6 1903 p.

**Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors**

Castellano, D., Grande, E., Valle, J., Capdevila, J., Reidy-Lagunes, D., O'Connor, J. M. & Raymond, E., 2015, In: *Cancer Chemother Pharmacol.* 75, 6, p. 1099-114 984 p.

**Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement**

Adaway, J. E., Dobson, R., Walsh, J., Cuthbertson, D. J., Monaghan, P. J., Trainer, P. J., Valle, J. W. & Keevil, B. G., 2015, In: *Ann Clin Biochem.*

**Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial**

Pavel, M., Horsch, D., Caplin, M., Ramage, J., Seufferlein, T., Valle, J., Banks, P., Lapuerta, P., Sands, A., Zambrowicz, B., Fleming, D. & Wiedenmann, B., 2015, In: *J Clin Endocrinol Metab.* 100, 4, p. 1511-9 1501 p.

**The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma**

Howell, M. & Valle, J. W., 2015, In: *Best Pract Res Clin Gastroenterol.* 29, 2, p. 333-43 289 p.

**Variation in Cardiac Screening and Management of Carcinoid Heart Disease in the UK and Republic of Ireland**

Dobson, R., Valle, J. W., Burgess, M. I., Poston, G. J. & Cuthbertson, D. J., 2015, In: *Clin Oncol (R Coll Radiol).* 27, 12, p. 741-6 734 p.

**Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality**

Dobson, R., Burgess, M., Valle, J., Pritchard, D., Vora, J., Wong, C., Chadwick, C., Keevi, B., Adaway, J., Hofmann, U., Poston, G. & Cuthbertson, D., 28 Oct 2014, In: *B J C.* 111, p. 1703-1709 6 p.

**Circulating biomarkers in hepatocellular carcinoma**

Morris, K., Tugwood, J., Khoja, L., Lanchashire, M., Burt, D., Shenjere, P., Zhou, C., Hodgson, C., Ohtomo, T., Kato, A., Ishiguro, T., Valle, J. & Dive, C., 1 Aug 2014, In: *Cancer Chemotherapy and Pharmacology.* 74, 2, p. 323-332 9 p.

**Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial**

Middleton, G., Silcocks, P., Cox, T., Valle, J., Wadsley, J., Propper, D., Coxon, F., Ross, P., Madhusudan, S., Roques, T., Cunningham, D., Falk, S., Wadd, N., Harrison, M., Corrie, P., Iveson, T., Anus, R. A., McAdam, K., Eatock, M. & Evans, J. & 13 others, Archer, C., Hickish, T., Garcia-Alonso, A., Nicolson, M., Steward, W., Anthoney, A., Greenhalf, W., Shaw, V., Costello, E., Naisbitt, D., Rawcliffe, R., Nanson, G. & Neoptolemos, J., Jul 2014, In: *The Lancet Oncology.* 15, 8, p. 829-840 11 p.

**Evaluation of hypertension and proteinuria as markers of efficacy in anti-angiogenic therapy for metastatic colorectal cancer.**

Khoja, L., Kumaran, G., Zee, Y., Murukesh, N., Swindell, R., Saunders, M., Clamp, A., Valle, J. W., Wilson, J., Jayson, G. & Hasan, J., May 2014, In: *Journal of clinical gastroenterology.* 48, 5, p. 430-434 4 p.

**Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: Ongoing lessons from the ESPAC-3 study**

Valle, J. W., Palmer, D., Jackson, R., Cox, T., Neoptolemos, J. P., Ghaneh, P., Rawcliffe, C. L., Bassi, C., Stocken, D. D., Cunningham, D., O'Reilly, D., Goldstein, D., Robinson, B. A., Karapetis, C., Scarfe, A., Lacaine, F., Sand, J., Izbicki, J. R., Mayerle, J. & Dervenis, C. & 8 others, Oláh, A., Butturini, G., Lind, P. A., Middleton, M. R., Anthoney, A., Sumpter, K., Carter, R. & Büchler, M. W., 20 Feb 2014, In: *Journal of Clinical Oncology.* 32, 6, p. 504-512 8 p.

**Cisplatin and gemcitabine for advanced biliary tract cancer: A meta-analysis of two randomised trials**

Valle, J. W., Furuse, J., Jitlal, M., Beare, S., Mizuno, N., Wasan, H., Bridgewater, J. & Okusaka, T., Feb 2014, In: *Annals of Oncology.* 25, 2, p. 391-398 7 p., mdt540.

**The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer**

Annels, N. E., Shaw, V. E., Gabitass, R. F., Billingham, L., Corrie, P., Eatock, M., Valle, J., Smith, D., Wadsley, J., Cunningham, D., Pandha, H., Neoptolemos, J. P. & Middleton, G., Feb 2014, In: *Cancer Immunology, Immunotherapy.* 63, 2, p. 175-183 8 p.



**Clinical management of targeted therapies in neuroendocrine tumours**

Carter, L., Hubner, R. A. & Valle, J. W., 1 Jan 2014, *Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract: From Surgery to Targeted Therapies: A Multidisciplinary Approach*. Paris: Springer Nature, p. 141-154 14 p.

**A comparison of diagnostic imaging modalities for colorectal liver metastases**

Bonanni, L., De'Liguori Carino, N., Deshpande, R., Ammori, B. J., Sherlock, D. J., Valle, J. W., Tam, E. & O'Reilly, D. A., 2014, In: *European Journal of Surgical Oncology*. 40, 5, p. 545-550 5 p.

**A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours**

Valle, J., Eatock, M., Clueit, B., Gabriel, Z., Ferdinand, R. & Mitchell, S., 2014, In: *Cancer Treatment Reviews*. 40, 3, p. 376-389 13 p.

**BINGO: targeted therapy for advanced biliary-tract cancer**

Valle, J., 2014, In: *The Lancet Oncology*. 15, 8, p. 778-780 2 p.

**capecitabine and streptozotocin+/- cisplatin in advanced gastroenteropancreatic neuroendocrine tumours**

Meyer, T., Qian, W., Caplin, M., Armstrong, G., Lao-Sirieix, S., Hardy, R., Valle, J., Talbot, D., Cunningham, D., Reed, N., Shaw, A., Navalkisoor, S., Luong, T. & Corrie, P., 2014, In: *European Journal of Cancer*. 50, 5, p. 902-911 9 p.

**Combination therapy of 177Lu and 90Y Dototate for treatment of neuroendocrine cancer**

Ashton, C., Jeans, S. & Valle, J., 2014, In: *Nuclear Medicine Communications*. 35, 6, p. 585-587 2 p.

**Determination of the Optimal Echocardiographic Scoring System To Quantify Carcinoid Heart Disease**

Dobson, R., Cuthbertson, D. J., Jones, J., Valle, J. W., Keevil, B., Chadwick, C., Poston, G. P. & Burgess, M. I., 2014, In: *Neuroendocrinology*. 99, 2, p. 85-93 8 p.

**Looking Beyond Chemotherapy in Patients with Advanced, Well-differentiated, Pancreatic Neuroendocrine Tumors Source**

Lamarca, A., Hubner, R. & Valle, J., 2014, In: *Journal of OncoPathology*. 2, 1, p. 15-25 10 p.

**Methods for Adjusting for Bias Due to Crossover in Oncology Trials**

Ishak, K. J., Proskorovsky, I., Korytowsky, B., Sandin, R., Faivre, S. & Valle, J., 2014, In: *PharmacoEconomics*.

**Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial**

Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Lamb, R. F., Garner, E., Campbell, F., MacKey, J. R., Costello, E., Moore, M. J., Valle, J. W., McDonald, A. C., Carter, R., Tebbutt, N. C., Goldstein, D., Shannon, J., Dervenis, C., Glimelius, B. & Deakin, M. & 13 others, Charnley, R. M., Lacaine, F., Scarfe, A. G., Middleton, M. R., Anthony, A., Halloran, C. M., Mayerle, J., Oláh, A., Jackson, R., Rawcliffe, C. L., Scarpa, A., Bassi, C. & Büchler, M. W., 2014, In: *Journal of the National Cancer Institute*. 106, 1, djt347.

**Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study**

Rembielak, A. I., Jain, P., Jackson, A. S., Green, M. M., Santorelli, G. R., Whitfield, G. A., Crellin, A., Garcia-Alonso, A., Radhakrishna, G., Cullen, J., Taylor, M. B., Swindell, R., West, C. M., Valle, J., Saleem, A. & Price, P. M., 2014, In: *Translational Oncology*. 7, 1, p. 55-64 9 p.

**Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors**

Valle, J., Faivre, S., Hubner, R., Grande, E. & Raymond, E., 2014, In: *Cancer Treatment Reviews*. 40, 10, p. 1230-1238 8 p.

**Reply to the letter to the editor 'Second-line chemotherapy in advanced biliary cancer: the present now will later be past' by Vivaldi et al**

Lamarca, A., Hubner, R., Ryder, W. & Valle, J., 2014, In: *Annals of Oncology*. 25, 12, p. 2444-2445 1 p.

**Second-line chemotherapy in advanced biliary cancer: a systematic review**

Lamarca, A., Hubner, R., David, R. W. & Valle, J., 2014, In: *Annals of Oncology*. 25, 12, p. 2328-2338 10 p.

**. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations**

Abdel-Rahman, O., Lamarca, A., Valle, J. & Hubner, R., 2014, In: *Endocrine - Related Cancer*. 21, 6, p. R485-R93

**Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial**

Primrose, J., Falk, S., Finch-Jones, M., Valle, J., O'Reilly, D., Siriwardena, A., Hornbuckle, J., Peterson, M., Rees, M., Iveson, T., Hickish, T., Butler, R., Stanton, L., Dixon, E., Little, L., Bowers, M., Pugh, S., Garden, O. J., Cunningham, D. & Maughan, T. & 1 others, Bridgewater, J., 2014, In: *The Lancet Oncology*. 15, 6, p. 601-611 10 p.

**The Association of a Panel of Biomarkers with the Presence and Severity of Carcinoid Heart Disease: A Cross-Sectional Study**

Dobson, R., Burgess, M. I., Banks, M., Pritchard, D. M., Vora, J., Valle, J. W., Wong, C., Chadwick, C., George, K., Keevil, B., Adaway, J., Ardill, J. E. S., Anthony, A., Hofmann, U., Poston, G. J. & Cuthbertson, D. J., 12 Sept 2013, In: *PLoS ONE*. 8, 9, e73679.

**Outcome of second-line chemotherapy for biliary tract cancer**

Bridgewater, J., Palmer, D., Cunningham, D., Iveson, T., Gillmore, R., Waters, J., Harrison, M., Wasan, H., Corrie, P. & Valle, J., 2013, In: *European Journal of Cancer*. 49, 6, p. 1511

**Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk**

Dunlop, M. G., Dobbins, S. E., Farrington, S. M., Jones, A. M., Palles, C., Whiffin, N., Tenesa, A., Spain, S., Broderick, P., Ooi, L. Y., Domingo, E., Smillie, C., Henrion, M., Frampton, M., Martin, L., Grimes, G., Gorman, M., Semple, C., Ma, Y. P. & Thomas, H. & 30 others, Evans, G., Henderson, A., Green, A., Smith, C. G., MacDonald, G., Smith, D., Grogan, L., Thomas, R., Wilson, R., Hindley, A., Susnerwala, S., Levine, E., Mullamitha, S., Saunders, M., Valle, J., Jones, A., Butt, M., Wilson, D., Harrison, M., Birtle, A., Webb, A., Jones, A., O'Neill, P., Cooper, R., Alexander, E., Toy, E., Williams, R., Adams, R., Parker, C. & Brown, J., 1 Jul 2012, In: *Nature Genetics*. 44, 7, p. 770-776 7 p.

**A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker**

Khoja, L., Backen, A., Sloane, R., Menasce, L., Ryder, D., Krebs, M., Board, R., Clack, G., Hughes, A., Blackhall, F., Valle, J. W. & Dive, C., 31 Jan 2012, In: *British Journal of Cancer*. 106, 3, p. 508-516 8 p.

**Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)**

Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V., Meyer, T., Newell-Price, J., Poston, G., Reed, N., Rockall, A., Steward, W., Thakker, R. V., Toubanakis, C., Valle, J. & Verbeke, C. & 1 others, Grossman, A. B., Jan 2012, In: *Gut*. 61, 1, p. 6-32 26 p.

**Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial**

Neoptolemos, J., Moore, M., Cox, T., Valle, J., Palmer, D., McDonald, A., Carter, R., Tebbutt, N., Dervenis, C., Smith, D., Glimelius, B., Charnley, R., Lacaine, F., Ag, S., Middleton, M., Anthony, A., Ghaneh, P., Halloran, C., Lerch, M. & Olah, A. & 4 others, Rawcliffe, C., Verbeke, C., Campbell, F. & Buchler, M., 2012, In: *JAMA Internal Medicine*. 308, p. 147-156 9 p.

**Sunitinib for advanced pancreatic neuroendocrine tumours**

Hubner, R. & Valle, J., Dec 2011, In: *Expert Review of Anticancer Therapy*. 11, 12, p. 1817-1827 10 p.

**A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction**

Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K. & Ranson, M., Oct 2011, In: *Investigational new drugs*. 29, 5, p. 1029-1037 8 p.

**Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer**

Furuse, J., Okusaka, T., Bridgewater, J., Taketsuna, M., Wasan, H., Koshiji, M. & Valle, J., Oct 2011, In: Critical Reviews in Oncology/Hematology. 80, 1, p. 31-39 8 p.

**A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection**

Wong, R., Cunningham, D., Barbachano, Y., Saffery, C., Valle, J., Hickish, T., Mudan, S., Brown, G., Khan, A., Wotherspoon, A., Strimpakos, A. S., Thomas, J., Compton, S., Chua, Y. J. & Chau, I., Sept 2011, In: Annals of Oncology. 22, 9, p. 2042-2048 6 p.

**randomized placebo-controlled, phase III study of oxaliplatin, fluorouracil and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma**

Van, C. E., Bajetta, E., Valle, J., Kohne, C., Hect, J., Moore, M., Germond, C., Berg, W., Chen, B., Jalava, T., Lebwohl, D., Meinhardt, G., Laurent, D. & Lin, E., 20 May 2011, In: Journal of Clinical Oncology. 29, 15, p. 2004-2010 6 p.

**Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study**

Waddell, T., Gollins, S., Soe, W., Valle, J., Allen, J., Bentley, D., Morris, J., Lloyd, A., Swindell, R., Taylor, M. B. & Saunders, M. P., May 2011, In: Cancer Chemotherapy and Pharmacology. 67, 5, p. 1111-1117 6 p.

**Sunitinib malate for the treatment of pancreatic neuroendocrine tumors**

Raymond, E., Dahan, L., Raoul, J., Bang, Y., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., Chen, J., Horsch, D., Hammel, P., Wiedenmann, B., Van, C. E., Patyna, S., Lu, D., Blanckmeister, C., Chao, R. & Ruzniewski, P., 10 Feb 2011, In: New England Journal Of Medicine. 364, 6, p. 501-513 12 p.

**Reply: Guesstimates are not good enough for determining what is happening in routine care**

Shabaruddin, F. H., Elliott, R. A., Valle, J. W., Newman, W. G. & Payne, K., 7 Dec 2010, In: British Journal of Cancer. 103, 12, p. 1887-1888 2 p.

**Advances in the treatment of metastatic or unresectable biliary tract cancer**

Valle, J. W., Oct 2010, In: Annals of Oncology. 21, 7, p. v345-v348

**Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomised controlled trial**

Neoptolemos, J., Stocken, D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, M., Gallinger, S., Mariette, C., Wente, M., Izbicki, J., Friess, H., Lerch, M., Dervenis, C., Olah, A., Butturini, G., Doi, R., Lind, P. & Smith, D. & 7 others, Valle, J., Palmer, D., Buckles, J., Thompson, J., McKay, C., Rawcliffe, C. & Buchler, M., 9 Sept 2010, In: JAMA Internal Medicine. 304, 10, p. 1073-1081 8 p.

**Efficacy and Tolerability of Limited Field Radiotherapy with Concurrent Capecitabine in Locally Advanced Pancreatic Cancer**

Jackson, A. S. N., Jain, P., Watkins, G. R., Whitfield, G. A., Green, M. M., Valle, J., Taylor, M. B., Dickinson, C., Price, P. M. & Saleem, A., Sept 2010, In: Clinical Oncology. 22, 7, p. 570-577 7 p.

**Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom**

Shabaruddin, F., Elliott, R., Valle, J., Newman, W. & Payne, K., 27 Jul 2010, In: British Journal of Cancer. 103, 3, p. 315-323 9 p.

**Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer**

Valle, J., Wasan, H., Palmer, D., Cunningham, D., Anthony, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughers, S., Pereira, S., Roughton, M. & Bridgewater, J., 8 Apr 2010, In: New England Journal Of Medicine. 362, 14, p. 1273-1281 8 p.

**Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer**

Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D., Steward, W., Harper, P. G., Dunn, J., Tudur-Smith, C., West, J., Falk, S., Crellin, A., Adab, F., Thompson, J., Leonard, P., Ostrowski, J., Eatock, M., Scheithauer, W., Herrmann, R. & Neoptolemos, J. P., 20 Nov 2009, In: *Journal of Clinical Oncology*. 27, 33, p. 5513-5518 5 p.

**Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: A multicentre randomised phase II study- the UK ABC-01 Study**

Valle, J. W., Wasan, H., Johnson, P., Jones, E., Dixon, L., Swindell, R., Baka, S., Maraveyas, A., Corrie, P., Falk, S., Gollins, S., Lofts, F., Evans, L., Meyer, T., Anthony, A., Iveson, T., Highley, M., Osborne, R. & Bridgewater, J., 18 Aug 2009, In: *British Journal of Cancer*. 101, 4, p. 621-627 6 p.

**UGT1A1\*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan**

Ferraldeschi, R., Minchell, L. J., Roberts, S. A., Tobi, S., Hadfield, K., Blackhall, F., Mullamitha, S., Wilson, G., Valle, J., Saunders, M. & Newman, W., 1 May 2009, In: *Pharmacogenomics*. p. 733-739

**Cholangiocarcinoma Management at the Christie between 2000 and 2004-Clinical Audit**

Rembielak, A., Whitfield, G., Watkins, G., Valle, J., Saleem, A., Dickinson, C. & Price, P., 2009, In: *Clinical Oncology*. 21, 3, p. 277-277 1 p.

**Phase II Study of Cetuximab and Radiotherapy in Patients with Locally Advanced Pancreatic Cancer (PACER Study)**

Rembielak, A., Saleem, A., Valle, J., West, C., Jackson, A., Crellin, A., Whitfield, G., Dickinson, C., Jain, P., Cullen, J., Watkins, G. & Price, P., 2009, In: *Clinical Oncology*. p. 254-255 2 p.

**Systemic treatment options for advanced biliary tract cancer**

Valle, J., 2009, In: *Current Treatment Options in Oncology*. 10, p. 67-72 5 p.

**A Phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumours**

Albanell, J., Montagut, C., Jones, E., Pronk, L., Mellado, B., Beech, J., Gascon, P., Zugmaier, G., Brewster, M., Saunders, M. & Valle, J., May 2008, In: *Clinical Cancer Research*. 14, 9, p. 2726-2731 5 p.

**A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer**

Clamp, A., Schoffski, P., Valle, J., Wilson, R., Marreaud, S., Govaerts, A., Debois, M., Lacombe, D., Twelves, C., Chick, J. & Jayson, G., Apr 2008, In: *Cancer Chemotherapy and Pharmacology*. 61, 4, p. 579-585 6 p.

**A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer**

Clamp, A. R., Schöffski, P., Valle, J. W., Wilson, R. H., Marreaud, S., Govaerts, A. S., Debois, M., Lacombe, D., Twelves, C., Chick, J. & Jayson, G. C., Apr 2008, In: *Cancer Chemotherapy and Pharmacology*. 61, 4, p. 579-585 6 p.

**Pneumoperitoneum following percutaneous biliary intervention: Not necessarily a cause for alarm**

Amonkar, S. J., Laasch, H. U. & Valle, J. W., Mar 2008, In: *Cardiovascular and Interventional Radiology*. 31, 2, p. 439-443 4 p.

**A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre**

Molassiotis, A., Saunders, M. P., Valle, J., Wilson, G., Lorigan, P., Wardley, A., Levine, E., Cowan, R., Loncaster, J. & Rittenberg, C., Feb 2008, In: *Supportive Care in Cancer*. 16, 2, p. 201-208 7 p.

**Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer**

Sheikh, H., Valle, J., Waddell, T., Palmer, K., Wilson, G., Sjursen, A., Craven, O., Swindell, R. & Saunders, M., 2008, In: *B J C*. 99, p. 577-583 6 p.

**Efficacy and toxicity of limited field concurrent chemoradiotherapy (CRT) with capecitabine for locally advanced pancreatic cancer (LAPC)**

Jain, P., Watkins, G., Jackson, A., Dickinson, C., Whitfield, G., Rembielak, A., Valle, J. W., Taylor, M. B., Price, P. M. & Saleem, A., 2008, In: *Journal of Clinical Oncology*. 26, 15

**Phase I evaluation of CDP791, a PEGylated Di-Fab' conjugate that binds vascular endothelial growth factor receptor 2**

Ton, N., Parker, G., Jackson, A., Mullamitha, S., Buonaccorsi, G., Roberts, C., Watson, Y., Davies, K., Cheung, S., Hope, L., Power, F., Lawrance, J., Valle, J., Saunders, M., Felix, R., Soranson, J., Rolfe, L., Zinkewich-Peotti, K. & Jayson, G., 1 Dec 2007, In: *Clinical Cancer Research*. 13, 23, p. 7113-7118 5 p.

**Phase I evaluation of CDP791, a PEGylated Di-Fab' conjugate that binds vascular endothelial growth factor receptor 2**

Ton, N. C., Parker, G. J. M., Jackson, A., Mullamitha, S., Buonaccorsi, G. A., Roberts, C., Watson, Y., Davies, K., Cheung, S., Hope, L., Power, F., Lawrance, J., Valle, J., Saunders, M., Felix, R., Soranson, J. A., Rolfe, L., Zinkewich-Peotti, K. & Jayson, G. C., 1 Dec 2007, In: *Clinical Cancer Research*. 13, 23, p. 7113-7118 5 p.

**Phase I evaluation of a fully human anti- $\alpha$ v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumours**

Mullamitha, S., Ton, N., Parker, G., Jackson, A., Julyan, P., Roberts, C., Buonaccorsi, G., Watson, Y., Davies, K., Cheung, S., Valle, J., Hope, L., Radford, J., Lawrance, J., Saunders, M., Munteanu, M., Nakada, M., Nemeth, J., Davis, H. & Jiao, Q. & 5 others, Prabhaker, U., Lang, Z., Corringham, R., Beckman, R. & Jayson, G., 1 Apr 2007, In: *Clinical Cancer Research*. 13, 2, p. 128-135 7 p.

**Phase I evaluation of a fully human anti- $\alpha$ v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors**

Mullamitha, S. A., Ton, N. C., Parker, G. J. M., Jackson, A., Julyan, P. J., Roberts, C., Buonaccorsi, G. A., Watson, Y., Davies, K., Cheung, S., Hope, L., Valle, J. W., Radford, J. A., Lawrance, J., Saunders, M. P., Munteanu, M. C., Nakada, M. T., Nemeth, J. A., Davis, H. M. & Jiao, Q. & 5 others, Prabhakar, U., Lang, Z., Corringham, R. E., Beckman, R. A. & Jayson, G. C., 1 Apr 2007, In: *Clinical Cancer Research*. 13, 7, p. 2128-35 8 p.

**Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: A Phase I study**

Sheikh, H. Y., Valle, J. W., Palmer, K., Sjursen, A., Craven, O., Wilson, G., Swindell, R. & Saunders, M. P., 15 Jan 2007, In: *British Journal of Cancer*. 96, 1, p. 38-43 5 p.

**Metastatic colorectal cancer: Current systemic treatment options**

Board, R. E. & Valle, J. W., 2007, In: *Drugs*. 67, 13, p. 1851-1867 16 p.

**Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma**

Falk, S., Anthoney, A., Eatock, M., Van Cutsem, E., Chick, J., Glen, H., Valle, J. W., Drolet, D. W., Albert, D., Ferry, D. & Ajani, J., 21 Aug 2006, In: *British Journal of Cancer*. 95, 4, p. 450-456 6 p.

**Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumour antigen 5T4 (TroVax) induces immune responses which correlates with disease control: a phase I/II trial**

Harrop, R., Connolly, N., Redchenko, I., Valle, J., Saunders, M., Ryan, M., Myers, K., Drury, N., Kingsman, S., Hawkins, R. & Carroll, M., 1 Jun 2006, In: *Clinical Cancer Research*. 12, 11 Pt 1, p. 3416-3424 8 p.

**A phase II study of weekly cisplatin and gemcitabine in patients with advanced pancreatic cancer: Is this a strategy still worth pursuing?**

Clayton, A. J., Mansoor, A. W., Jones, E. T., Hawkins, R. E., Saunders, M. P., Swindell, R. & Valle, J. W., Jan 2006, In: *Pancreas*. 32, 1, p. 51-57 6 p.

**Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor**

Whitworth, M. K., Sheen, A., Rosa, D. D., Duff, S. E., Ryder, D., Burumdayal, A., Wiener, K., Hawkins, R. E., Saunders, M., Valle, J. W., Sherlock, D. & Jayson, G. C., Jan 2006, In: *Journal of Cancer Research and Clinical Oncology*. 132, 1, p. 41-4 4 p.

**Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): Results of a phase II study**

Valle, J. W., Dangoor, A., Beech, J., Sherlock, D. J., Lee, S. M., Scarffe, J. H., Swindell, R. & Ranson, M., 28 Feb 2005, In: *British Journal of Cancer*. 92, 4, p. 628-630 2 p.

**Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer**

Saunders, H. P., Hogg, M., Carrington, B., Sjrursen, A. M., Allen, J., Beech, J., Swindell, R. & Valle, J. W., 18 Oct 2004, In: British Journal of Cancer. 91, 8, p. 1447-1452 5 p.

**Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer**

Ross, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., Price, T., Anderson, H., Iveson, T., Hickish, T., Lofts, F. & Norman, A., 15 Apr 2002, In: Journal of Clinical Oncology. 20, 8, p. 1996-2004 8 p.

**New face for a familiar friend: The deGramont regimen in the treatment of metastatic colorectal cancer given as an outpatient: A feasibility study**

Valle, J., Rowe, M., Walle, J. W., Swindell, R., Fitzsimmons, L. & James, R. D., 2002, In: Journal of Oncology Pharmacy Practice. 8, 2-3, p. 97-103 6 p.

**Prospective randomized trial comparing mitomycin, cisplatin and protracted venous-infusion fluorouracil (PV1 5-FU) with epirubicin, cisplatin and PV1 5-FU in advanced esophagogastric cancer**

Ross, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., Price, T., Anderson, H., Iveson, T., Hickish, T., Lofts, F. & Norman, A., 2002, In: Journal of Clinical Oncology. 20, 8, p. 1996-2004 8 p.

**Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma**

Thatcher, N., White, S. C., Lorigan, P., Middleton Heather Anderson, M. R., Valle, J., Summers, Y., Burt, P. A., Arance, A., Stout, R. & Thatcher, N., 1 Aug 2001, In: Cancer. 92, 3, p. 601-608 7 p.

**Randomised phase II study of CAV (cyclophosphamide-adriamycin-vincristine) versus single agent carboplatin in poor prognosis small cell lung cancer**

White, S., Lorigan, P., Middleton, M., Anderson, H., Valle, J., Summers, Y., Burt, P. A., Arance, A., Stout, R. & Thatcher, N., 2001, In: Cancer. 92

**Review of recent trials of chemotherapy for advanced breast cancer: Studies excluding taxanes**

Demons, M., Leahy, M., Valle, J., Jayson, G., Ranson, M., Hayes, S. & Howell, A., Nov 1997, In: European Journal of Cancer. 33, 13, p. 2171-2182 11 p.

**Review of recent trials of chemotherapy for advanced breast cancer: The Taxanes**

Demons, M., Leahy, M., Valle, J., Jayson, G., Ranson, M. & Howell, A., Nov 1997, In: European Journal of Cancer. 33, 13, p. 2183-2193 10 p.

**Sexuality in women receiving chemotherapy for breast cancer**

Valle, J., Clemons, M., Hayes, S., Fallowfield, L. & Howell, A., Jun 1997, In: Annals of Oncology. 8, 6, p. 616-8 3 p.

**Citrobacter freundii and fatal neutropenic enterocolitis following adjuvant chemotherapy for breast cancer**

Clemons, M., Valle, J., Harris, M., Weaver, A., Ellenbogen, S. & Howell, A., Apr 1997, In: Annals of Oncology. 8, 4, p. 405

**Citrobacter freundii and fatal neutropenic enterocolitis following adjuvant chemotherapy for breast cancer**

Clemons, M. J., Valle, J. W., Harris, M., Ellenbogen, S. & Howell, A., 1997, In: Clinical oncology (Royal College of Radiologists (Great Britain)). 9, 3, p. 172-5 4 p.

## Activities

## Awards

## Projects

**ABC-08, A phase 1b multi-centre, open-label study of a first-in-class nucleotide analogue Acelarin (NUC-1031) in combination with cisplatin in patients with locally advanced/metastatic biliary tract cancers**

Mcnamara, M. (PI) & Valle, J. (Col)

23/12/15 → 31/03/20

**A Study to Assess the Feasibility of Evaluating BRCAness in Plasma and Tumour Samples from Patients with Advanced Pancreatic Adenocarcinoma.**

Mcnamara, M. (PI) & Valle, J. (Col)

4/09/18 → 3/09/20

**Collins Pancreatic Cancer UK Scholarship.**

Valle, J. (PI) & McNamara, M. (Col)

1/04/16 → 30/09/19

**Development of an Alternative 'Precision Medicine' Platform for Identifying and Testing Novel Therapeutic Strategies for Advanced Extra-Pulmonary (EP), Poorly Differentiated (PD), Neuroendocrine Carcinoma (NEC).**

Mcnamara, M. (PI), Dive, C. (Col) & Valle, J. (Col)

1/07/18 → 30/06/19

**NIHR Manchester Biomedical Research Centre**

Bruce, I. (PI), Lord, G. (Col), Lennon, R. (Col), Black, G. (Col), Wedge, D. (Col), Morris, A. (Col), Hussell, T. (Col), Sharrocks, A. (Col), Stivaros, S. (Col), Buch, M. (Col), Gough, J. (Col), Kostarelos, K. (Col), Thistlethwaite, F. (Col), Kadler, K. (Col), Barton, A. (Col), Hyrich, K. (Col), Mcbeth, J. (Col), O'Neill, T. (Col), Vestbo, J. (Col), Simpson, A. (Col), Singh, S. (Col), Smith, J. (Col), Felton, T. (Col), Murray, C. (Col), Griffiths, C. (Col), Cullum, N. (Col), Rhodes, L. (Col), Warren, R. (Col), Paus, R. (Col), Dumville, J. (Col), Viros Usandizaga, A. (Col), Keavney, B. (Col), Tomaszewski, M. (Col), Allan, S. (Col), Body, R. (Col), Cartwright, E. (Col), Heagerty, A. (Col), Kalra, P. (Col), Miller, C. (Col), Rutter, M. (Col), Smith, C. (Col), Trafford, A. (Col), Evans, D. (Col), Crosbie, E. (Col), Crosbie, P. (Col), Harvie, M. (Col), Howell, S. (Col), Renehan, A. (Col), Dive, C. (Col), Blackhall, F. (Col), Landers, D. (Col), Krebs, M. (Col), Cook, N. (Col), Clarke, R. (Col), Taylor, S. (Col), Jorgensen, C. (Col), Lorigan, P. (Col), Jayson, G. (Col), Valle, J. (Col), McCabe, M. (Col), Armstrong, A. (Col), Freitas, A. (Col), Illidge, T. (Col), Choudhury, A. (Col), Hoskin, P. (Col), West, C. (Col), Van Herk, M. (Col), Faivre-Finn, C. (Col), Bristow, R. (Col), Kirkby, K. (Col), Birtle, A. (Col), Mackay, R. (Col), Radford, J. (Col), Linton, K. (Col), Higham, C. (Col), Munro, K. (Col), Plack, C. (Col), Arden Armitage, C. (Col), Bruce, I. (Col), Moore, D. (Col), Saunders, G. (Col), Stone, M. (Col), Haddock, G. (Col), Lewis, S. (Col), Elliott, R. (Col), Green, J. (Col), Lovell, K. (Col), Morrison, A. (Col), Shaw, J. (Col), Bucci, S. (Col), Ainsworth, J. (Col), Webb, R. (Col), Newman, W. (Col), Banka, S. (Col), Clayton-Smith, J. (Col), Payne, K. (Col), Moldovan, R. (Col), Wynn, R. (Col) & Jones, S. (Col)

1/12/22 → 30/11/27

## Impacts

**Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (ABC-02). N Engl J Med 362(14): 1273-81**

Valle, J. (Corresponding participant)

**Defining immunotherapy in combination with chemotherapy as first-line treatment of patients with advanced biliary tract cancer (durvalumab)**

Valle, J. (Corresponding participant) & McNamara, M. (Participant)

**Defining the role of second-line chemotherapy for patients with advanced / inoperable biliary tract cancer (FOLFOX (oxaliplatin/5FU))**

Valle, J. (Corresponding participant)

**Establishing a standard of care treatment for biliary tract cancer patients following surgery (capecitabine)**

Valle, J. (Corresponding participant)

**Improved treatment option for patients with previously treated IDH-1 mutated cholangiocarcinoma (bile duct cancer) (Ivosidenib)**

Valle, J. (Corresponding participant)

**Seeking better treatments for patients with intrahepatic cholangiocarcinoma (ICCA) and FGFR2 gene rearrangement (futibatinib)**

Valle, J. (Corresponding participant)

## **Datasets**

**Supplementary Material for: 68Gallium DOTANOC-PET Imaging in Lung Carcinoids: Impact on Patients' Management**

Lamarca, A. (Contributor), Pritchard, D. M. (Contributor), Westwood, T. (Contributor), Papaxoinis, G. (Contributor), Nonaka, D. (Contributor), Vinjamuri, S. (Contributor), Valle, J. (Contributor), Manoharan, P. (Contributor) & Mansoor, W. (Contributor), figshare , 16 May 2017

DOI: 10.6084/m9.figshare.5008877.v1, [https://figshare.com/articles/Supplementary\\_Material\\_for\\_68Gallium\\_DOTANOC-PET\\_Imaging\\_in\\_Lung\\_Carcinoids\\_Impact\\_on\\_Patients\\_Management/5008877/1](https://figshare.com/articles/Supplementary_Material_for_68Gallium_DOTANOC-PET_Imaging_in_Lung_Carcinoids_Impact_on_Patients_Management/5008877/1) and one more link, <https://ndownloader.figshare.com/files/8439359> (show fewer)

**Supplementary Material for: Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary**

Singh, S. (Creator), Carnaghi, C. (Creator), Buzzoni, R. (Creator), Pommier, R. F. (Creator), Raderer, M. (Creator), Tomasek, J. (Creator), Lahner, H. (Creator), Valle, J. (Creator), Voi, M. (Creator), Bubuteishvili-Pacaud, L. (Creator), Lincy, J. (Creator), Wolin, E. (Creator), Okita, N. (Creator), Libutti, S. K. (Creator), Oh, D.-Y. (Creator), Kulke, M. (Creator), Strosberg, J. (Creator), Yao, J. C. (Creator), Pavel, M. E. (Creator) & Fazio, N. (Creator), figshare , 18 Jul 2017

DOI: 10.6084/m9.figshare.5217421